Search Result
Results for "
rat neurons
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
5
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-W004260
-
|
Eicosanoic acid
|
Endogenous Metabolite
|
Neurological Disease
|
|
Arachidic acid is an orally bioavailable membrane fluidity modulator and receptor/ion channel effector. Arachidic acid does not activate arachidonic acid-sensitive K + channels in rat midbrain and hypothalamic neurons. Arachidic acid alleviates age-related spatial cognitive impairment. Arachidic acid is applicable for research related to age-related spatial cognitive impairment .
|
-
-
- HY-P0198
-
-
-
- HY-10864
-
URB-597
5 Publications Verification
KDS-4103
|
FAAH
Autophagy
Mitophagy
|
Neurological Disease
|
|
URB-597 (KDS-4103) is an orally bioavailable and selective FAAH inhibitor. URB-597 inhibits FAAH activity with an IC50s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity .
|
-
-
- HY-P1944A
-
Apelin-13 TFA
Maximum Cited Publications
10 Publications Verification
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
Metabolic Disease
|
|
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .
|
-
-
- HY-B0168A
-
|
|
Serotonin Transporter
PERK
|
Neurological Disease
|
|
Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
-
- HY-121119
-
|
|
Adenosine Receptor
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
MRS 1523 is a potent and selective adenosine A3 receptor antagonist with Ki values of 18.9 nM and 113 nM for human and rat A3 receptors, respectively. In rat this corresponds to selectivities of 140- and 18-fold vs A1 and A2A receptors, respectively. MRS 1523 can exert antihyperalgesic effect through N-type Ca channel block and action potential inhibition in isolated rat dorsal root ganglion (DRG) neurons .
|
-
-
- HY-P5912
-
|
|
iGluR
Calcium Channel
|
Neurological Disease
|
|
GluN1 (356-385) is a polypeptide targeting NMDAR GluN1. GluN1 (356-385) induces the production of autoantibodies, which reduce the density of cell surface NMDAR clusters, impair long-term potentiation, and decrease NMDAR-mediated Ca 2+ influx. As an immunogen, GluN1 (356-385) induces symptoms similar to anti-NMDAR encephalitis, including memory loss, in mice. GluN1 (356-385) can be used to establish a mouse model that mimics the pathogenesis of anti-NMDAR encephalitis. GluN1 (356-385) is applicable to research related to anti-NMDAR encephalitis .
|
-
-
- HY-B0596
-
|
TA-0910
|
Thyroid Hormone Receptor
Apoptosis
|
Neurological Disease
Endocrinology
|
|
Taltirelin (TA-0910) is an orally effective analogue of thyrotropin releasing hormone (TRH) and a TRH receptor (TRH-R) superagonist (IC50 at 910 nM). Taltirelin can cross the blood-brain barrier. Taltirelin stimulates an increase in cytosolic Ca 2+ concentration (Ca 2+ release) with an EC50 value of 36 nM. Taltirelin increases cell viability and reduces apoptosis in SH-SY5Y cells and primary rat mesencephalic neurons treated with MPP+ (HY-W008719) or Rotenone (HY-B1756). Taltirelin has neuroprotective effects in both cellular and animal models of Parkinson's disease. Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue .
|
-
-
- HY-120751
-
|
|
Calcium Channel
|
Neurological Disease
|
|
TROX-1 is a selective, orally active and brain-penetrant N-type calcium channel (Cav2.2) inhibitor with an IC50 value of 0.11 μM. TROX-1 exerts state-dependent and use-dependent inhibition, preferentially targets open/inactivated channels, blocks depolarization-associated calcium influx, and fully blocks calcium influx in rat dorsal root ganglion neurons. TROX-1 reverses inflammatory-induced hyperalgesia, nerve injury-induced allodynia. TROX-1 can be used for the research of pain .
|
-
-
- HY-N0061
-
|
|
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
|
Ethyl ferulate, a naturally lipophilic derivative of ferulic acid originally derived from Rhizoma Chuanxiong, induces heme oxygenase-1 (HO-1) and protects rat neurons against oxidative stress . Ethyl ferulate also protects neurons against amyloid β peptide (1-42)-induced oxidative stress and neurotoxicity .
|
-
-
- HY-100371
-
|
alpha-MCPG
|
mGluR
|
Neurological Disease
|
|
(RS)-MCPG (alpha-MCPG) is a competitive and selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. (RS)-MCPG blocks theta-burst stimulation (TBS)-induced shifts in both juvenile and neonatal rat hippocampal neurons .
|
-
-
- HY-P1080
-
|
|
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
ω-Agatoxin IVA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50 values of 2 nM and 90 nM. ω-Agatoxin IVA inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA inhibits Capsaicin (HY-10448)-induced CGRP release and vasodilation. ω-Agatoxin IVA can be used for the research of neurological and cardiovascular disease .
|
-
-
- HY-P2543
-
|
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Neuropeptide Y (3-36) (human, rat) is a neuropeptide Y fragment derived from humans or rats. Neuropeptide Y is an extremely abundant neurotransmitter in central and peripheral neurons, and it participates in the regulation of psychomotor activity, circadian rhythm, feeding behavior and cardiovascular function. Neuropeptide Y (3-36) (human, rat) can serve as a substrate to be sequentially degraded from its N-terminus by AfuS28, and it requires binding to AfuS28 and SedB to be decomposed into amino acids, dipeptides and tripeptides [1] [2].
|
-
-
- HY-P1205A
-
|
Melanin-concentrating hormone(human, mouse, rat) TFA
|
MCHR1 (GPR24)
|
Neurological Disease
Metabolic Disease
|
|
MCH (human, mouse, rat) TFA is a cyclic neuropeptide mainly synthesized by neurons in the lateral hypothalamic area. MCH (human, mouse, rat) TFA also serves as an endogenous ligand for the melanin-concentrating hormone receptor (MHC receptor), with a binding IC50 of 0.3 nM and 1.5 nM for human MCH-1R and MCH-2R, respectively; its functional EC50 values are 3.9 nM and 88.7 nM. MCH (human, mouse, rat) TFA acts not only as an orexigenic signal but also as a key integrating and regulatory hormone for energy homeostasis and sleep-wake cycles. MCH (human, mouse, rat) TFA can be used in studies related to obesity, sleep disorders, and other associated conditions .
|
-
-
- HY-N2160
-
|
|
GABA Receptor
|
Neurological Disease
|
|
6'''-Feruloylspinosin is a flavonoid isolated from seeds of Ziziphus jujuba. 6'''-Feruloylspinosin can across the blood-brain barrier and enhance the expression of GABAAα1, GABAAα5, and GABABR1 mRNA in rat hippocampal neurons .
|
-
-
- HY-122635A
-
|
|
Histone Demethylase
|
Neurological Disease
|
|
T-448 is a specific, orally active, CNS-penetrant and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC50 of 22 nM. T-448 enhances H3K4 methylation in primary cultured rat neurons .
|
-
-
- HY-U00050
-
|
E-10-OH-NT
|
Drug Metabolite
Adrenergic Receptor
mAChR
|
Neurological Disease
|
|
(E)-10-Hydroxynortriptyline (E-10-OH-NT) is a blood-brain barrier-permeable norepinephrine uptake inhibitor. (E)-10-Hydroxynortriptyline effectively promotes central norepinephrine neuronal transmission, with little interindividual variation in in vivo potency. (E)-10-Hydroxynortriptyline has low affinity for muscarinic receptors, exhibits only extremely weak anticholinergic activity, and does not inhibit salivary secretion. (E)-10-Hydroxynortriptyline can be used in studies related to depression .
|
-
-
- HY-W013712
-
|
|
Potassium Channel
|
Neurological Disease
|
|
GI-530159 is a selective opener of TREK1 and TREK2 potassium channels. GI-530159 displays selectivity for TREK1/2 over TRAAK, TASK3 and other potassium channels, with an EC50 of 0.76 μM for TREK1. GI-530159 reduces rat dorsal root ganglion neuron excitability and shows potential analgesic effect .
|
-
-
- HY-103234A
-
|
|
iGluR
|
Neurological Disease
|
|
GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .
|
-
-
- HY-132814
-
|
ATH-1017
|
c-Met/HGFR
|
Neurological Disease
|
|
Fosgonimeton (ATH-1017) is a hepatocyte growth factor receptor (c-Met/HGFR) agonist. Fosgonimeton has neuroprotective effects in both LPS (HY-D1056) -induced neuroinflammation and Aβ-induced AD models .
|
-
-
- HY-B0596A
-
|
TA-0910 acetate
|
Thyroid Hormone Receptor
Apoptosis
|
Neurological Disease
Endocrinology
|
|
Taltirelin acetate (TA-0910) is an acetate form of Taltirelin (TA-0910). Taltirelin (TA-0910) is an orally effective analogue of thyrotropin releasing hormone (TRH) and a TRH receptor (TRH-R) superagonist (IC50 at 910 nM). Taltirelin can cross the blood-brain barrier. Taltirelin stimulates an increase in cytosolic Ca 2+ concentration (Ca 2+ release) with an EC50 value of 36 nM. Taltirelin increases cell viability and reduces apoptosis in SH-SY5Y cells and primary rat mesencephalic neurons treated with MPP+ (HY-W008719) or Rotenone (HY-B1756). Taltirelin has neuroprotective effects in both cellular and animal models of Parkinson's disease. Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue .
|
-
-
- HY-W073501
-
|
trans-2-Pentenedioic acid
|
Drug Isomer
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
trans-Glutaconic acid (trans-2-Pentenedioic acid) is the trans isomer of Glutaconic acid (HY-W073501A). trans-Glutaconic acid is a neurotoxic metabolite. trans-Glutaconic acid induces weak neurotoxicity in cultured cerebral neocortical neurons. trans-Glutaconic acid elicits significant electrophysiological responses in rat neocortical wedge preparations at high concentrations. trans-Glutaconic acid can be used in studies related to glutaric acidemia type 1 .
|
-
-
- HY-P0198A
-
-
-
- HY-18663
-
|
|
iGluR
|
Neurological Disease
|
|
CP-465022 is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .
|
-
-
- HY-N8249
-
|
|
nAChR
Interleukin Related
|
Inflammation/Immunology
|
|
Cynandione A is an acetophenone that can be isolated from Cynanchum Wilfordii Radix. Cynandione A protects hepatocytes and cortical neurons from toxicity and improves neurological deficits in a rat model of cerebral ischemia. On the other hand, cynandione A has significant anti-inflammatory effects and inhibits inflammation by activating macrophage α7 nAChR and IL-10 expression .
|
-
-
- HY-160959
-
|
|
nAChR
|
Neurological Disease
|
|
AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with Ki of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP +. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .
|
-
-
- HY-P1387
-
|
|
Amyloid-β
Apoptosis
|
Neurological Disease
|
|
β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases 45Ca 2+ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease .
|
-
-
- HY-W004425
-
|
3,7-Dimethyl-1-propargylxanthine
|
Adenosine Receptor
|
Neurological Disease
|
|
DMPX (3,7-Dimethyl-1-propargylxanthine) is a selective A2A adenosine receptor (A2A AR) antagonist that crosses the blood-brain barrier, with a Ki of 11 μM for rat A2 adenosine receptor and a Ki of 45 μM for rat A1 adenosine receptor. By blocking A2A receptors in specific brain regions, DMPX protects dopaminergic and GABAergic neurons from mitochondrial dysfunction. DMPX is applicable to research related to depression, Parkinson's disease and Huntington's disease .
|
-
-
- HY-106865
-
|
|
Dopamine Receptor
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research .
|
-
-
- HY-B0168
-
|
|
Serotonin Transporter
PERK
|
Neurological Disease
|
|
Milnacipran is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran inhibits pERK1/2 activation. Milnacipran has antidepressant, anxiolytic and analgesic properties. Milnacipran inhibits biting behavior in mice. Milnacipran can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
-
- HY-162653
-
|
|
|
Others
|
|
SGC-CDKL2/AAK1/BMP2K-1 (Compound 9) is a potent and selective CDKL2 (Cyclin-dependent kinase-like 2) inhibitor with an IC50 value of 460 nM. CDKL2 is involved in various biological processes such as tumorigenesis, development, and viral infections. SGC-CDKL2/AAK1/BMP2K-1 serves as a powerful tool for studying the biological functions of CDKL2 and holds promise for research in fields related to cancer, infections, and other diseases .
|
-
-
- HY-100547
-
|
|
iGluR
|
Neurological Disease
|
|
IEM-1754, a dicationic adamantane derivative, is a potent blocker of open channels of native ionotropic glutamate receptors including quisqualate-sensitive receptors in insect muscles, NMDAR in cultured rat cortical neurons, and AMPAR in freshly isolated hippocampal cells. IEM-1754 shows anticonvulsant potency in vivo .
|
-
-
- HY-105022
-
|
R 58735
|
Tau Protein
|
Neurological Disease
|
|
Sabeluzole (R 58735), a benzothiazol derivative, has antiischemic, antiepileptic, and cognitive-enhancing properties. Sabeluzole protects rat hippocampal neurons against NMDA- and glutamate-induced neurotoxicity via preventing tau expression. Sabeluzole enhances memory in rats, and prevents the amnesic effect of Chlordiazepoxide. Sabeluzole can be used fro research of Alzheimer's disease .
|
-
-
- HY-P3071
-
|
Stichodactyla helianthus neurotoxin
|
Potassium Channel
|
Neurological Disease
Inflammation/Immunology
|
|
ShK toxin blocks voltage-dependent potassium channel (Kv1.3 channel). ShK toxin can be isolated from the whole body extract of the Caribbean sea anemone (Stichodactylu helianthus). ShK toxin competes with dendrotoxin I and α-dendrotoxin for binding to synaptosomal membranes of rat brain, facilitates acetylcholine release. ShK toxin suppresses K+ currents in cultured rat dorsal root ganglion neurons. ShK toxin also inhibits T lymphocyte proliferation .
|
-
-
- HY-P1205
-
|
Melanin-concentrating hormone(human, mouse, rat)
|
MCHR1 (GPR24)
|
Neurological Disease
Metabolic Disease
|
|
MCH (human, mouse, rat) is a cyclic neuropeptide mainly synthesized by neurons in the lateral hypothalamic area. MCH (human, mouse, rat) also serves as an endogenous ligand for the melanin-concentrating hormone receptor (MHC receptor), with a binding IC50 of 0.3 nM and 1.5 nM for human MCH-1R and MCH-2R, respectively; its functional EC50 values are 3.9 nM and 88.7 nM. MCH (human, mouse, rat) acts not only as an orexigenic signal but also as a key integrating and regulatory hormone for energy homeostasis and sleep-wake cycles. MCH (human, mouse, rat) can be used in studies related to obesity, sleep disorders, and other associated conditions .
|
-
-
- HY-103502
-
CGP7930
1 Publications Verification
|
GABA Receptor
|
Neurological Disease
|
|
CGP7930 (3-(3’,5’-Di-tert-butyl-4’-hydroxy) phenyl-2, 2-dimethylpropanol) is a positive metabotropic GABAB receptor allosteric modulator. CGP7930 enhances the inhibitory effect of l-baclofen on the oscillatory activity of cultured cortical neurons .
|
-
-
- HY-111560
-
|
|
Potassium Channel
|
Neurological Disease
|
|
IQM-266 is a Downstream Regulatory Element Antagonist Modulator (DREAM) ligand with a KD of 4.63 μM. IQM-266 inhibits the KV4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner. IQM-266 also modulates A-type outward potassium currents (IA) from rat dorsal root ganglia (DRG) neurons. IQM-266 can be used for neurological disease research, such as Alzheimer’s disease and Huntington's disease (HD) .
|
-
-
- HY-108479
-
|
SR140333
|
Neurokinin Receptor
|
Neurological Disease
|
|
Nolpitantium (SR140333) is a potent, selective, competitive, non-peptide tachykinin NK1 receptor antagonist. Nolpitantium blocks the activation of rat thalamic neurons after nociceptive stimulation .
|
-
-
- HY-151962
-
|
|
JNK
Apoptosis
GSK-3
p38 MAPK
|
Neurological Disease
|
|
JNK3 inhibitor-5 (Compound 22b) is a potent and selective JNK3 inhibitor with an IC50 of 0.379 nM. JNK3 inhibitor-5 effectively protects the neuronal cells against amyloid beta-induced apoptosis. JNK3 inhibitor-5 has a high cell permeability and is predicted as BBB permeable .
|
-
-
- HY-P10360
-
|
|
α-synuclein
|
Neurological Disease
|
|
Tat-βsyn-degron is an α-synuclein knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders .
|
-
-
- HY-P3528
-
|
|
Caspase
Apoptosis
|
Neurological Disease
|
|
GPR is a three amino acid peptide. GPR can rescue cultured rat hippocampal neurons from Aβ-induced neuronal death by inhibiting caspase-3/p53 dependent apoptosis. GPR can be used for the research of Alzheimer's disease (AD).
|
-
-
- HY-108671
-
|
|
P2X Receptor
|
Neurological Disease
|
|
NF110 is a P2X3 receptor antagonist (Ki = 36 nM) and inactive toward P2Y receptors stably expressed (IC50s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC50 = 527 nM) in rat dorsal root ganglia neurons .
|
-
-
- HY-10864R
-
|
KDS-4103 (Standard)
|
FAAH
Autophagy
Mitophagy
Reference Standards
|
Neurological Disease
|
|
URB-597 (Standard) is the analytical standard of URB-597. This product is intended for research and analytical applications. URB-597 (KDS-4103) is an orally bioavailable and selective FAAH inhibitor. URB-597 inhibits FAAH activity with an IC50s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity .
|
-
-
- HY-114975
-
|
|
iGluR
|
Neurological Disease
|
|
EGIS-8332 is a non-competitive AMPA receptor antagonist. EGIS-8332 inhibits AMPA currents in rat cerebellar Purkinje cells and inhibited the AMPA- and Quisqualate-induced excitotoxicity in primary cultures of telencephalon neurons (IC50 = 5.1-9.0 μM). EGIS-8332 exhibits anticonvulsant and neuroprotective effects. EGIS-8332 can be used for the research of neurological disease .
|
-
-
- HY-12914
-
|
|
TRP Channel
|
Neurological Disease
Inflammation/Immunology
|
|
V116517 is a potent, orally active transient receptor potential vanilloid (TRPV1) antagonist. V116517 shows potent activity in inhibiting both capsaicin (CAP)- and acid (pH 5)-induced currents in rat DRG neurons expressing native TRPV (IC50=423.2 nM for CAP; IC50=180.3 nM for acid). V116517 can be used for the research of pain .
|
-
-
- HY-119495
-
|
|
Thyroid Hormone Receptor
|
Neurological Disease
|
|
JTP 2942 is a thyrotropin-releasing hormone analogue. JTP 2942 can promote the release of Acetylcholine in the hippocampus and frontal cortex of rats. JTP 2942 possesses neuroprotective and cognitive-improving activities. JTP 2942 dose-dependently improves motor and neurological deficits in rat models of chronic focal cerebral ischemia. JTP 2942 can be used for the research of cerebral ischemia, motor neuron diseases, and other related conditions .
|
-
-
- HY-P3071A
-
|
Stichodactyla helianthus neurotoxin TFA
|
Potassium Channel
|
Neurological Disease
Inflammation/Immunology
|
|
ShK toxin TFA (Stichodactyla helianthus neurotoxin TFA) is a neurotoxin. ShK toxin TFA blocks voltage-dependent potassium channel (Kv1.3 channel). ShK toxin TFA can be isolated from the whole body extract of the Caribbean sea anemone (Stichodactylu helianthus). ShK toxin TFA competes with dendrotoxin I and α-dendrotoxin for binding to synaptosomal membranes of rat brain, facilitates acetylcholine release. ShK toxin TFA suppresses K + currents in cultured rat dorsal root ganglion neurons. ShK toxin TFA also inhibits T lymphocyte proliferation .
|
-
-
- HY-B0822S1
-
|
|
GABA Receptor
Cytochrome P450
|
Inflammation/Immunology
|
|
Fipronil- 13C6 is the 13C-labeled Fipronil. Fipronil is an insecticide that acts as a selective antagonist of insect GABA receptors (IC50s = 30 nM and 1,600 nM for cockroach and rat receptors, respectively). Fipronil also inhibits desensitizing and non-desensitizing glutamate-induced chloride currents in cockroach neurons (IC50s = 800 nM and 10 nM, respectively). Fipronil induces activity of the cytochrome P450 (CYP) isoforms CYP1A1/2, CYP2B1/2, and CYP3A1/2 in isolated rat liver microsomes.
|
-
-
- HY-19858
-
|
|
iGluR
|
Neurological Disease
|
|
LY-466195 is a selective and competitive GLUK5 receptor antagonist. LY-466195 antagonizes Kainate-induced currents with an IC50 value of 0.045 μM in rat dorsal root ganglion neurons. In HEK293 cells transfected with GLUK5, GLUK2/GLUK5, or GLUK5/GLUK66 receptors, LY466195 produces IC50 values of 0.08 μM, 0.34 μM, and 0.07 μM, respectively .
|
-
-
- HY-103338
-
|
|
Others
|
Neurological Disease
|
|
AM1172 is metabolically stable anandamide uptake inhibitor. AM1172 inhibits [ 3H] anandamide transport in rat cortical neurons and human CCF-STTG1 astrocytoma cells with IC50 values of 2.1 μM and 2.5 μM, respectively. AM1172 can significantly inhibit AEA hydrolysis and concurrently decrease AEA uptake. AM1172 can be used for the study of endocannabinoid system regulation .
|
-
- HY-P1474
-
|
Amyloid β-Protein (22-35)
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35), the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
- HY-P1474A
-
|
Amyloid β-Protein (22-35) TFA
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
- HY-P1001A
-
|
|
Caspase
Apoptosis
|
Neurological Disease
Cancer
|
|
Ac-DEVD-CHO TFA is a peptide inhibitor of caspase-3 (Ki=230 pM) and caspase-7. Ac-DEVD-CHO TFA reduces caspase-3 activity and apoptosis induced by Prostaglandin E2 (HY-101952) in rat cortical neurons. Ac-DEVD-CHO TFA is promising for research of neurodegenerative diseases and cancers .
|
-
- HY-149500
-
-
- HY-15082
-
|
BIIR 561
|
iGluR
Sodium Channel
|
Neurological Disease
|
|
Irampanel (BIIR 561) is an AMPA receptor and voltage-dependent sodium channel blocker. Irampanel inhibits kainate-induced currents in rat cortical neurons .
|
-
- HY-120308
-
|
SR140603
|
Neurokinin Receptor
|
Neurological Disease
|
|
(R)-Nolpitantium is the R-enantiomer of Nolpitantium (HY-108479). Nolpitantium (SR140333) is a potent, selective, competitive, non-peptide tachykinin NK1 receptor antagonist. Nolpitantium blocks the activation of rat thalamic neurons after nociceptive stimulation .
|
-
- HY-133166
-
|
|
TRP Channel
|
Neurological Disease
|
|
A-889425 is an oral active selective TRPV1 receptor antagonist with the with an IC50 of 335 nM (rat) and 34 nM (human). A-889425 has good penetration into the CNS and reduces mechanical allodynia and spinal neuron responses to mechanical stimulation of Complete Freund's adjuvant (HY-153808)-inflamed rat hind paws .
|
-
- HY-155017
-
|
|
Sodium Channel
|
Neurological Disease
Cancer
|
|
6-Iodoamiloride is a potent acid-sensing ion channel 1 (ASIC1) inhibitor with an IC50 of 88 nM. 6-Iodoamiloride inhibits ASIC3-mediated currents from rat dorsal root ganglion neurons with an IC50 of 230 nM .
|
-
- HY-P5179
-
|
HWTX-I
|
Calcium Channel
Sodium Channel
|
Neurological Disease
|
|
Huwentoxin I (HWTX-I) is a peptide toxin that inhibits voltage-gated sodium channels and N-type calcium channels. Huwentoxin I inhibits sodium channels in rat hippocampus and cockroach dorsal unpaired median (DUM) neurons with IC50 values of 66.1 and 4.80 nM, respectively .
|
-
- HY-P5773
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Jingzhaotoxin-34, a 35-residue polypeptide, is a neurotoxin. Jingzhaotoxin-34 inhibits tetrodotoxin-sensitive (TTX-S) sodium currents (IC50 of ~85 nM) while having no significant effects on tetrodotoxin-resistant (TTX-R) sodium currents on rat dorsal root ganglion neurons .
|
-
- HY-P5180
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Jingzhaotoxin-V is a peptide that inhibits potassium currents in Xenopus laevis oocytes with an IC50 value of 604.2 nM. Jingzhaotoxin-V also inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive sodium currents in rat dorsal root ganglion neurons with IC50 values of 27.6 and 30.2 nM, respectively .
|
-
- HY-178153
-
|
|
iGluR
|
Neurological Disease
|
|
BPAM363 is an orally active, selective positive allosteric modulator (PAM) of AMPARs with blood-brain barrier penetration. BPAM363 selectively potentiates AMPAR activity in human and rat models, with an EC2x value of 0.96 μM in rat embryonic cortex primary neurons. BPAM363 upregulates BDNF protein expression in rat primary cortical neuronal cultures. BPAM363 enhances AMPA-mediated excitatory postsynaptic responses in rat and mice. BPAM363 can be used for the study of cognitive disorders .
|
-
- HY-P0198B
-
-
![[D-Arg25]-Neuropeptide Y (human)](//file.medchemexpress.com/product_pic/hy-p0198b.gif)
- HY-18663B
-
|
|
iGluR
|
Neurological Disease
|
|
CP-465022 hydrochloride is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .
|
-
- HY-18663A
-
|
|
iGluR
|
Neurological Disease
|
|
CP-465022 Maleate is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .
|
-
- HY-121122
-
|
|
TRP Channel
|
Others
|
A778317 is a TRPV1 antagonists. A778317 can block changes in intracellular calcium levels mediated by TRPV1 receptors, with a pIC50 value of 8.31. A-778317 can also block the activation of natural rat TRPV1 receptors in dorsal root ganglion neurons by capsaicin and acid .
|
-
- HY-122635
-
|
|
Histone Demethylase
|
Neurological Disease
|
|
T-448 free base is a specific, orally active, CNS-penetrant and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC50 of 22 nM. T-448 free base enhances H3K4 methylation in primary cultured rat neurons .
|
-
- HY-100458
-
|
|
NO Synthase
|
Neurological Disease
|
|
SCR-4026 is a neuroprotective agent with blood-brain barrier penetration ability. SCR-4026 exerts neuroprotective effects by disrupting the interaction between neuronal nNOS and PSD9, with an IC50 of 6.3 μM. SCR-4026 alleviates N-methyl-D-aspartate (NMDA)-induced excitotoxic damage in primary cortical neurons, and also protects neurons in the oxygen-glucose deprivation (OGD) model. SCR-4026 can reduce the cerebral infarct volume in the rat middle cerebral artery occlusion (MCAO) reperfusion model. SCR-4026 can be used for the study of stroke .
|
-
- HY-121119R
-
|
|
Adenosine Receptor
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
MRS 1523 (Standard) is the analytical standard of MRS 1523. This product is intended for research and analytical applications. MRS 1523 is a potent and selective adenosine A3 receptor antagonist with Ki values of 18.9 nM and 113 nM for human and rat A3 receptors, respectively. In rat this corresponds to selectivities of 140- and 18-fold vs A1 and A2A receptors, respectively. MRS 1523 can exert antihyperalgesic effect through N-type Ca channel block and action potential inhibition in isolated rat dorsal root ganglion (DRG) neurons .
|
-
- HY-15076
-
|
NS-1209 sodium
|
iGluR
|
Neurological Disease
|
|
SPD-502 sodium is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 sodium effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 sodium may be promising for studying neurodegenerative conditions associated with glutamate excitotoxicity .
|
-
- HY-15074
-
|
NS-1209
|
iGluR
|
Neurological Disease
|
|
SPD-502 is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 may be promising for studying neurodegenerative conditions associated with glutamate excitotoxicity .
|
-
- HY-168859
-
|
|
JNK
GSK-3
Amyloid-β
|
Neurological Disease
|
|
JNK3 inhibitor-9 (Compound 24a) is a potent, selective and BBB-permeable JNK3 inhibitor with an IC50 value of 12 nM. JNK3 inhibitor-9 also potently inhibits GSK3α/β (IC50s: 14 and 35 nM, respectively) involved in Tau phosphorylation. JNK3 inhibitor-9 reduces c-Jun and APP phosphorylation. JNK3 inhibitor-9 protects neurons from Aβ1-42 toxicity .
|
-
- HY-100371R
-
|
alpha-MCPG (Standard)
|
Reference Standards
mGluR
|
Neurological Disease
|
|
(RS)-MCPG (Standard) is the analytical standard of (RS)-MCPG. This product is intended for research and analytical applications. (RS)-MCPG (alpha-MCPG) is a competitive and selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. (RS)-MCPG blocks theta-burst stimulation (TBS)-induced shifts in both juvenile and neonatal rat hippocampal neurons .
|
-
- HY-P5770
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Jingzhaotoxin-V, a 29-residue polypeptide, is derived from the venom of the spider Chilobrachys jingzhao. Jingzhaotoxin-V inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive sodium currents in rat dorsal root ganglion neurons with IC50 values of 27.6 nM and 30.2 nM, respectively. Jingzhaotoxin-V also inhibits Kv4.2 potassium currents expressed in Xenpus Laevis oocytes (IC50 of 604.2 nM) .
|
-
- HY-103234
-
|
|
iGluR
|
Neurological Disease
|
|
GYKI 52466 is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research .
|
-
- HY-103234B
-
|
|
iGluR
|
Neurological Disease
|
|
GYKI 52466 hydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 hydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 hydrochloride can be used in Parkinson's disease research .
|
-
- HY-103234AR
-
|
|
Reference Standards
iGluR
|
Neurological Disease
|
|
GYKI 52466 (dihydrochloride) (Standard) is the analytical standard of GYKI 52466 (dihydrochloride). This product is intended for research and analytical applications. GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .
|
-
- HY-105022R
-
|
R 58735 (Standard)
|
Reference Standards
Tau Protein
|
Neurological Disease
|
|
Sabeluzole (Standard) is the analytical standard of Sabeluzole. This product is intended for research and analytical applications. Sabeluzole (R 58735), a benzothiazol derivative, has antiischemic, antiepileptic, and cognitive-enhancing properties. Sabeluzole protects rat hippocampal neurons against NMDA- and glutamate-induced neurotoxicity via preventing tau expression. Sabeluzole enhances memory in rats, and prevents the amnesic effect of Chlordiazepoxide. Sabeluzole can be used fro research of Alzheimer's disease .
|
-
- HY-130358
-
|
|
Calcium Channel
|
Neurological Disease
|
|
PDDHV is a calcium absorption inducer and may achieve 45Ca 2+ influx by stimulating vanillic acid receptor VR1. PDDHV induces 45Ca 2+ uptake (EC50: 70 nM) in rat dorsal root ganglion neurons (expressing native vanilloid receptors) and calcium mobilization (EC50: 125 nM) in VR1-transfected CHO cells. PDDHV also inhibits [3H]-resiniferatoxin (RTX) binding to the dorsal root ganglion membrane in rats .
|
-
- HY-P5782
-
|
|
Sodium Channel
|
Neurological Disease
|
|
δ-Theraphotoxin-Hm1a toxin is a selective Nav1.1 activator. δ-Theraphotoxin-Hm1a toxin elicits pain and touch sensitivity. δ-Theraphotoxin-Hm1a toxin can be used for the research of irritable bowel syndrome .
|
-
- HY-B0168AR
-
|
|
Reference Standards
Serotonin Transporter
PERK
|
Neurological Disease
|
|
Milnacipran (hydrochloride) (Standard) is the analytical standard of Milnacipran hydrochloride (HY-B0168A). This product is intended for research and analytical applications. Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
- HY-B0168AS
-
|
|
Isotope-Labeled Compounds
Serotonin Transporter
PERK
|
Neurological Disease
|
|
Milnacipran-d5 hydrochloride is deuterium labeled Milnacipran hydrochloride (HY-B0168A). Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
- HY-162347
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Nav1.7-IN-13 (compound 3g) is a sodium channel inhibitor that significantly inhibits Veratridine (HY-N6691)-induced neuronal activity. Nav1.7-IN-13 inhibits total Na+ current in DRG neurons in a concentration-dependent manner; slows down the activation of Navs. Nav1.7-IN-13 significantly alleviated mechanical pain behavior in a rat model of nerve injury (SNI) and had analgesic activity .
|
-
- HY-132227
-
|
3',4'-Dichlorobenzamil hydrochloride; L-594881 hydrochloride
|
Na+/Ca2+ Exchanger
|
Others
|
|
Dichlorobenzamil (3',4'-Dichlorobenzamil; L-594881) hydrochloride is a Na +-Ca 2+ Exchanger inhibitor. Dichlorobenzamil (hydrochloride) attenuates the Na +-Ca 2+ exchanger-mediated inward current induced by activation of type I metabotropic glutamate receptors in second-order baroreceptor neurons of the rat nucleus tractus solitarius .
|
-
- HY-182504
-
|
|
Dopamine Receptor
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
NRA‑0562 is a dopamine antagonist with high affinities for dopamine D1/D2/D3/D4, 5‑HT2A and α1‑adrenoceptors. NRA-0562 dose‑dependently reverses induced suppression of firing activity in rat A9 and A10 midbrain dopamine neurons, with preferential potency at A10 neurons (ED50 = 0.3 mg/kg). NRA-0562 elevates Fos-like immunoreactivity in rat nucleus accumbens and dorsolateral striatum. NRA-0562 can be used for preclinical research on schizophrenia . .
|
-
- HY-W714853
-
|
|
Akt
Src
STAT
EGFR
Drug Isomer
|
Neurological Disease
Inflammation/Immunology
|
|
(+)-Theta-cypermethrin is a stereoisomer of Cypermethrin (HY-B0829) that possesses blood-brain barrier penetration ability and binds to AKT1, SRC, STAT3 and EGFR with high affinity. (+)-Theta-cypermethrin reduces the amplitude of delayed rectifier potassium channel currents, shifts the steady-state activation curve to negative potentials, and shifts the steady-state inactivation curve to negative potentials at higher concentrations. (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons. (+)-Theta-cypermethrin causes chronic respiratory system damage and exhibits neurotoxicity .
|
-
- HY-173142
-
|
|
Drug Derivative
|
Neurological Disease
|
|
Neuroprotective agent 7 (Compound 13) is a BBB-penetrable neuroprotective agent. Neuroprotective agent 7 has a powerful neuroprotective effect and can reduce the cerebral infarct area in the MCAO rat model. Neuroprotective agent 7 can be used in the research of diseases such as cerebral ischemia .
|
-
- HY-15083
-
|
BIIR-561-CL
|
iGluR
Sodium Channel
|
Neurological Disease
|
|
Irampanel hydrochloride (BIIR 561-CL) is an AMPA receptor and voltage-dependent sodium channel blocker. Irampanel hydrochloride inhibits Kainic acid (HY-N2309)-induced currents in rat cortical neurons .
|
-
- HY-182539
-
|
|
CGRP Receptor
|
Others
Neurological Disease
|
|
DD04107 is a neuronal exocytosis inhibitor with a rat Syt1-C2B domain binding Ka of 2.4 μM. DD04107 interferes with synaptobrevin-syntaxin-SNAP-25 complex formation and Syt1-SNARE complex interaction to block α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons. DD04107 blocks inflammatory ion channel recruitment to nociceptor plasma membranes. DD04107 can be used for the research of chronic inflammatory pain, neuropathic pain, osteosarcoma pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, inflammatory pain .
|
-
- HY-186170A
-
-
- HY-P991815
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD90.1 Antibody (OX-7) reacts with the mouse and rat CD90.1. CD90 is present on a variety of cell types in murine and rat, including lymphatic vessels, T cells, neurons and fibroblasts. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-180345
-
|
|
Prostaglandin Receptor
|
Neurological Disease
|
|
ND-7001 is an inhibitor of PDE2 with an IC50 of 0.05 μM. ND-7001 exhibits good selectivity agianst PDE3 and PDE4. ND-7001 increases cGMP levels in primary neuronal cultures of rat cerebral cortical neurons. ND-7001 displays anxiolytic effects .
|
-
- HY-126939
-
|
|
Reactive Oxygen Species (ROS)
Calcium Channel
iGluR
|
Neurological Disease
|
|
MN-05 is a dual neuroprotective and vasodilatory NMDA receptor inhibitor.MN-05 blocks calcium influx, reduces free radical production, and maintains mitochondrial membrane potential in cortical neurons exposed to glutamate.MN-05 dilates aortic rings against phenylephrine-induced contraction.MN-05 protects neurons against glutamate-induced injury in vitro.MN-05 can be used for the research of neurodegenerative diseases .
|
-
- HY-182631
-
|
|
iGluR
|
Neurological Disease
|
|
CX1763 is an AMPAR allosteric modulator. CX1763 allosterically potentiates glutamate-evoked currents, accelerates channel opening, and increases the surface levels of AMPAR containing Glur2 (R). CX1763 enhances synaptic transmission in the rat hippocampus. CX1763 improves attention in rats and attenuates amphetamine-induced hyperactivity in mice. CX1763 can be used in studies related to attention deficit hyperactivity disorder and opioid-induced respiratory depression .
|
-
- HY-131691
-
|
|
iGluR
Calcium Channel
|
Neurological Disease
|
|
NMDAR blocker 1 is an NMDA receptor channel blocker with an IC50 of 5.0 μM. NMDAR blocker 1 exhibits fast on-off blockade kinetics and strong voltage dependence, and does not compete with glutamate or glycine. NMDAR blocker 1 prevents glutamate/NMDA-induced intracellular Ca 2+ overload, modulates the glutamate-nitric oxide-cGMP pathway. NMDAR blocker 1 prevents in vitro excitotoxic neurodegeneration of cultured cerebellar and hippocampal neurons. NMDAR blocker 1 attenuates excitotoxic insult in an mouse model of hyperammonemia-induced excitotoxicity. NMDAR blocker 1 can be used for the research of neurodegenerative diseases .
|
-
- HY-186169A
-
-
- HY-165459
-
|
MK-056
|
TRP Channel
|
Infection
Inflammation/Immunology
|
|
KJM429 (MK-056) is a high-affinity ligand for the rat vanilloid receptor rTRPV1 (Ki=30-63 nM) with a unique dual regulatory function. KJM429 acts as a competitive antagonist to inhibit TRPV1 receptor activation induced by Capsaicin (HY-10448), resiniferatoxin, thermal stimulation and weak acid (pH 6.0), and switches to a TRPV1 agonist under strong acid conditions (pH<5.5). KJM429 effectively blocks calcium influx induced by Capsaicin and partial thermal stimulation, and triggers calcium uptake under low pH conditions, with minimal effects on non-TRPV1-mediated calcium signaling. KJM429 can be used for research on the mechanisms of pain-related diseases such as postherpetic neuralgia, diabetic neuropathy, cluster headache, osteoarthritis and pruritus .
|
-
- HY-186105A
-
|
|
Opioid Receptor
Apoptosis
|
Neurological Disease
|
|
(-)-P7C3-S243 is an orally active, blood-brain barrier permeable neuroprotective agent. (-)-P7C3-S243 binds to μ-opioid Receptor and TSPO. (-)-P7C3-S243 inhibits the premature apoptosis death of newborn hippocampal neurons, protects mature nigral dopaminergic neurons, promotes neuronal survival and prevents cognitive impairment. (-)-P7C3-S243 ameliorates depression-like behaviors in rat models. (-)-P7C3-S243 is applicable to research related to Parkinson's disease and Alzheimer's disease .
|
-
- HY-182548
-
|
|
GABA Receptor
Sodium Channel
iGluR
|
Cardiovascular Disease
Neurological Disease
|
|
BTS 72664 is a broad-spectrum, non-sedating, orally effective anticonvulsant. Its anticonvulsant effect mainly arises from enhancing GABAA receptor (GABAA receptor)-mediated chloride channel currents, while it exerts weak blocking effects on Na + channels (Ki = 350 μM) and NMDA receptors (NMDA receptor) (IC50 = 43 μM). BTS 72664 prevents the elevation of extracellular glutamate, glycine and serine concentrations in neurons, reduces cerebral infarct size, promotes functional recovery, prevents multiple types of epileptic seizures, and has low sedative potential. BTS 72664 can be used for the research of epilepsy, stroke and migraine .
|
-
- HY-182600
-
|
|
Kallikrein
Plasminogen/Plasmin
|
Neurological Disease
Inflammation/Immunology
|
|
KLK6-IN-1 is a reversible small‑molecule inhibitor of KLK6, KLK1, and plasmin. KLK6-IN-1 shows IC50 values of 1.57 μM (KLK6), 5.1 μM (KLK1), 7.4 μM (plasmin), and Ki values of 0.8 μM (KLK6), 2.4 μM (KLK1), 1.3 μM (plasmin). KLK6-IN-1 is highly selective for KLK6 and its proteolytic network. KLK6-IN-1 induces oligodendrocyte differentiation by promoting oligodendrocyte precursor cell maturation. KLK6-IN-1 can be used for the research of multiple sclerosis .
|
-
- HY-D2481
-
|
APG-2 TMA
|
Fluorescent Dye
|
Neurological Disease
|
|
Asante potassium green-2 (APG-2) TMA is a cell-impermeable K + (potassium ion) fluorescent indicator that produces a fluorescent response to changes in extracellular potassium ion concentration. Its excitation/emission maxima are 525/545 nm , respectively.
|
-
- HY-N8693
-
|
|
COX
Amyloid-β
Sirtuin
Reactive Oxygen Species (ROS)
Apoptosis
SARS-CoV
|
Infection
Neurological Disease
|
|
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .
|
-
- HY-B0358
-
-
- HY-B0358AR
-
|
|
Reference Standards
Calcium Channel
Sodium Channel
Dopamine Receptor
|
Neurological Disease
|
|
Flunarizine (dihydrochloride) (Standard) is the analytical standard of Flunarizine (dihydrochloride). This product is intended for research and analytical applications. Flunarizine dihydrochloride is a potent dual Na +/Ca 2+ channel (T-type) blocker. Flunarizine dihydrochloride is a D2 dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .
|
-
- HY-B0358R
-
|
|
Reference Standards
Calcium Channel
Sodium Channel
Dopamine Receptor
|
Neurological Disease
|
|
Flunarizine (Standard) is the analytical standard of Flunarizine. This product is intended for research and analytical applications. Flunarizine is a potent dual Na +/Ca 2+ channel (T-type) blocker. Flunarizine is a D2 dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .
|
-
- HY-125382A
-
|
|
Somatostatin Receptor
|
Neurological Disease
|
|
L-797591 hydrochloride is a selective sst1 agonist. L-797591 hydrochloride mimicks the effects of SRIF-14 and SRIF-28 by potently inhibiting either Forskolin (HY-15371)-stimulated or CRH-stimulated cAMP accumulation .
|
-
- HY-B0358A
-
-
- HY-B0358AS
-
-
- HY-P1944
-
Apelin-13
Maximum Cited Publications
10 Publications Verification
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
Metabolic Disease
|
|
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .
|
-
- HY-181482
-
|
|
DAGL
|
Neurological Disease
|
|
A1480LS is a peripherally restricted, orally active covalent and irreversible inhibitor of DAGLα and DAGLβ, with IC50 values of 6 nM and 4 nM against human targets, respectively, and IC50 values ≤15 nM across mouse, rat, dog, monkey and human systems. A1480LS reduces the levels of 2-arachidonoylglycerol, arachidonic acid, and cyclooxygenase- and lipoxygenase-derived eicosanoids. A1480LS inhibits injury-induced production of 2-arachidonoylglycerol and arachidonic acid in the peripheral sciatic nerve, and suppresses the responses of high-threshold and wide-dynamic-range-like dorsal horn neurons to mechanical stimulation. A1480LS alleviates pain behaviors in rat models of inflammatory pain, neuropathic pain and chemotherapy-induced peripheral neuropathy .
|
-
- HY-D3394
-
|
|
Fluorescent Dye
|
Others
|
|
SGC5 is a fluorescence enhancer and membrane dissociator with millisecond-scale membrane dissociation kinetics, with an emission spectrum of 500-650 nm. SGC5 produces strong fluorescence upon binding to lipid membranes, exhibits fast partitioning dissociation kinetics at higher temperatures, and is unaffected by pH or cholesterol. SGC5 does not belong to the FM dye family and shows the highest membrane-bound fluorescence intensity among the tested styryl/FM dyes. SGC5 can be used to study synaptic vesicle cycling in neurons .
|
-
- HY-120059
-
|
|
Potassium Channel
|
Neurological Disease
|
|
NS4591 is a modulator of calcium-activated potassium channels with activity that enhances small (SK) and intermediate (IK) conductivity. NS4591 doubled IK-mediated currents in whole-cell patch-clamp experiments at a concentration of 45 +/- 6 nM, and doubled SK3-mediated currents at a concentration of 530 +/- 100 nM. NS4591 inhibits the number of action potentials generated by suprathreshold depolarizing pulses in acutely isolated bladder primary afferent neurons. NS4591 also reduced carbakol-induced detrusor ring contraction in the rat bladder, demonstrating sensitivity to apamin .
|
-
- HY-185007
-
|
|
GABA Receptor
|
Neurological Disease
|
|
LI-633 is a selective and orally active GABAA receptor positive allosteric modulator (PAM) with a Ki of 21 nM. LI-633 produces robust potentiation of GABA-induced inward current, with EC50 values ranging from 8 nM (α5β2γ2) to 128 nM (α3β2γ2). LI-633 potentiates muscimol-induced GABAergic currents in rat dorsal root ganglion (DRG) neurons with an EC50 of 70.4 nM. LI-633 can be used for the study of visceral pain .
|
-
- HY-N14827
-
|
SM-216289
|
Drug Derivative
|
Neurological Disease
|
|
Xanthofulvin (SM-216289) is an inhibitor of semaphorin 3A. Xanthofulvin blocks its binding to receptors, inhibits growth cone collapse, and accelerates olfactory nerve regeneration in rats in vivo. Xanthofulvin can be used in studies related to traumatic neuronal injury .
|
-
- HY-100834A
-
|
5,7-DCKA sodium
|
iGluR
|
Neurological Disease
|
|
5,7-Dichlorokynurenic acid (5,7-DCKA) sodium is a selective and competitive antagonist of the glycine site on NMDA receptor with a KB of 65 nM. 5,7-Dichlorokynurenic acid sodium reduces NMDA-induced neuron injury. 5,7-Dichlorokynurenic acid sodium increases social interaction time, increases open arm exploration time, disinhibits suppressed conflict responding in rodent models. 5,7-Dichlorokynurenic acid sodium exhibits anxiolytic-like activity in rodent models and supports exploration of glycine’s role in NMDA receptor-mediated synaptic transmission .
|
-
- HY-100834
-
|
5,7-DCKA
|
iGluR
|
Neurological Disease
|
|
5,7-Dichlorokynurenic acid (5,7-DCKA) is a selective and competitive antagonist of the glycine site on NMDA receptor with a KB of 65 nM. 5,7-Dichlorokynurenic acid reduces NMDA-induced neuron injury. 5,7-Dichlorokynurenic acid increases social interaction time, increases open arm exploration time, disinhibits suppressed conflict responding in rodent models. 5,7-Dichlorokynurenic acid exhibits anxiolytic-like activity in rodent models and supports exploration of glycine’s role in NMDA receptor-mediated synaptic transmission .
|
-
- HY-150038
-
|
NBS-1120
|
NF-κB
Apoptosis
|
Neurological Disease
Cancer
|
|
NOSH-aspirin (NBS-1120) is an orally active hybrid molecule that releases nitric oxide and hydrogen sulfide. NOSH-aspirin inhibits pancreatic cancer cell proliferation and induces apoptosis. NOSH-aspirin inhibits cancer cell growth and suppresses NF-κB and FoxM1 in a mouse model of pancreatic cancer. NOSH-aspirin also alleviates motor deficits and dopaminergic neuron degeneration in a rat model of Parkinson's disease. NOSH-aspirin reduces neuroinflammation caused by microglial and astrocytic activation. NOSH-aspirin can be used in research on cancers such as pancreatic cancer and neurological diseases such as Parkinson's disease .
|
-
- HY-N6746
-
|
NSC 186
|
Bacterial
Fungal
Endogenous Metabolite
Apoptosis
|
Infection
Neurological Disease
Cancer
|
|
Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
|
-
- HY-P1248
-
|
NPFF
|
Neuropeptide FF Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Neuropeptide FF (NPFF), an octapeptide belonging to the RF-amide family of peptides, is a NPFF1 and NPFF2 receptors agonist with Ki values of 2.82 nM and 0.21 nM, respectively. Neuropeptide FF induces abstinence syndrome, exerts antiopioid and analgesic effects, releases via calcium-dependent mechanisms from rat spinal cord, regulates memory, autonomic function, and neuroendocrine function, modulates pain and opioid antinociception, reduces food intake, stimulates water intake, alters cardiovascular parameters, and shows differential activity in hypothalamic paraventricular nucleus neurons. Neuropeptide FF is present in mammalian central nervous system and periphery, with NPFF-immunoreactivity increases in rat cerebrospinal fluid during opiate tolerance, and its NPFF gene and NPFF-R2 gene are up-regulated in rat spinal cord and dorsal root ganglia during peripheral inflammation. Neuropeptide FF can be used for the research of opioid tolerance, morphine-induced analgesia, abstinence syndrome, pain, hypertension, nociception, inflammatory pain, and neuropathic pain .
|
-
- HY-204388
-
|
|
iGluR
Calcium Channel
|
Neurological Disease
|
|
TAK-137 is an AMPA receptor potentiator with weak agonistic effect. TAK-137 binds to the AMPA receptor ligand binding domain in a glutamate-dependent manner. TAK-137 potentiates AMPA-induced currents and Ca 2+ influx. TAK-137 can be used for the research of neurological disease .
|
-
- HY-P992426
-
|
|
Tau Protein
|
Neurological Disease
|
|
NS101 is an anti-FAM19A5 antibody with an IC50 of 0.2 nM and a Kd of 111 pM, as well as blood-brain barrier permeability. NS101 binds to key amino acid residues of FAM19A5, thereby blocking the interaction of LRRC4B and disrupting the FAM19A5-LRRC4B complex. NS101 increases the dendritic spine density in hippocampal neurons and the prefrontal cortex, normalizes the dendritic spine elimination rate, elevates the frequencies of mEPSC and fEPSP, and promotes the transport of brain-derived FAM19A5 into the peripheral circulation. NS101 improves cognitive function in mouse models of Alzheimer's disease. NS101 can be used for research on Alzheimer's disease. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P1278B
-
|
|
Neurokinin Receptor
|
Neurological Disease
Endocrinology
|
|
GR 64349 acetate is a selective neurokinin 2 (NK2) receptor agonist. GR 64349 acetate selectively activates the NK-2 receptor subtype. GR 64349 acetate activates tonic and rhythmic bladder contractions of the micturition reflex. GR 64349 acetate does not inhibit rhythmic bladder contraction activation induced by normal saline. GR 64349 acetate induces inward currents .
|
-
- HY-W002438
-
|
|
Biochemical Assay Reagents
Endogenous Metabolite
OAT
Ferroptosis
|
Neurological Disease
Metabolic Disease
|
|
6-Hydroxyindole is an orally active, endogenous long-acting OATP1B1 inhibitor. 6-Hydroxyindole does not alter the cell surface expression or subcellular localization of OATP1B1. 6-Hydroxyindole protects cells against Ferroptosis. 6-Hydroxyindole possesses intrinsic radical-trapping antioxidant activity. 6-Hydroxyindole serves as a component of oxidative hair dyes. 6-Hydroxyindole can be used in research related to renal failure and neurodegenerative diseases .
|
-
- HY-19820A
-
|
|
Akt
Ser/Thr Protease
Apoptosis
MMP
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
NSC45586 sodium is an inhibitor of PHLPP. NSC45586 sodium targets the PP2C phosphatase domains of PHLPP1 and PHLPP2, blocks the phosphatase activity of PHLPP, increases the expression level of FOXO1 in the nucleus, and reduces the protein expression of PHLPP1. NSC45586 sodium activates the AKT survival signaling pathway, enhances IGF-1-induced AKT activation, and inhibits the phosphorylation of AKT/ERK under basal conditions. NSC45586 sodium reduces staurosporine-induced neuronal death, preserves notochord cell morphology and KRT19 expression, inhibits cell apoptosis (apoptosis), improves the viability and proliferation of nucleus pulposus cells, upregulates the expression of ACAN/SOX9, and downregulates the expression of MMP13. NSC45586 sodium binds tightly to bovine serum albumin (bovine serum albumin), and exerts a more significant effect on nucleus pulposus in male individuals. NSC45586 sodium can be used in studies related to global cerebral ischemia and intervertebral disc degeneration .
|
-
- HY-182401
-
|
|
ERK
Akt
|
Neurological Disease
|
|
NS-417 free base is an ERK1, ERK2, and Akt kinase activator with neuroprotective, neurite outgrowth potentiating, and dopaminergic cell population enhancing activity. NS-417 free base enhances activation of ERK1, ERK2, and Akt kinase via growth factor stimulation. NS-417 free base rescues cells from growth factor withdrawal-induced death, stimulates neurite outgrowth, increases tyrosine hydroxylase-positive cell counts, and displays neurotrophic-like activity in in vitro models. NS-417 free base can be used for the research of parkinson’s disease .
|
-
- HY-120751A
-
|
|
Drug Isomer
Calcium Channel
|
Neurological Disease
|
|
(S)-TROX-1 is the S-enantiomer of TROX-1 (HY-120751). TROX-1 is a selective, orally active and brain-penetrant N-type calcium channel (Cav2.2) inhibitor with an IC50 value of 0.11 μM. TROX-1 exerts state-dependent and use-dependent inhibition, preferentially targets open/inactivated channels, blocks depolarization-associated calcium influx, and fully blocks calcium influx in rat dorsal root ganglion neurons. TROX-1 reverses inflammatory-induced hyperalgesia, nerve injury-induced allodynia. TROX-1 can be used for the research of pain .
|
-
- HY-100658
-
|
|
5-HT Receptor
Dopamine Receptor
|
Neurological Disease
|
|
Didesmethyl cariprazine is an orally active, BBB-permeable metabolite of Cariprazine (HY-14763). Didesmethyl cariprazine is a partial agonist at the D2 and D3 receptors, full agonist at the 5-HT1A receptor, and antagonist at the human 5-HT2B receptor (Ki: 1.41 nM (human D2L), 0.056 nM (human D3), 1.7 nM (human 5-HT1A), 0.52 nM (human 5-HT2B)). Didesmethyl cariprazine dose-dependently inhibits the spontaneous activity of rat midbrain dopaminergic neurons .
|
-
- HY-B0188
-
|
Mianserine
|
Histamine Receptor
Opioid Receptor
ERK
p38 MAPK
|
Neurological Disease
|
|
Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .
|
-
- HY-W005255R
-
|
|
Reference Standards
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Citrinin (Standard) is the analytical standard of Citrinin. This product is intended for research and analytical applications. Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
|
-
- HY-N6746R
-
|
NSC 186 (Standard)
|
Reference Standards
Bacterial
Fungal
Endogenous Metabolite
Apoptosis
|
Infection
Neurological Disease
Cancer
|
|
Citrinin (Standard) is the analytical standard of Citrinin. This product is intended for research and analytical applications. Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
|
-
- HY-147681
-
|
|
FGFR
|
Neurological Disease
|
|
SUN13837 is an orally active, blood-brain barrier permeable FGFR modulator and neuroprotective agent. SUN13837 mimics the activity of basic fibroblast growth factor, stimulates intracellular tyrosine phosphorylation of FGFR and signal transduction in neuronal cells, induces neurite outgrowth, and inhibits glutamate-induced neuronal death. SUN13837 can be used in research related to acute cervical spinal cord injury and severe spinal cord injury .
|
-
- HY-N0392
-
|
|
Toll-like Receptor (TLR)
PI3K
Akt
NF-κB
MDM-2/p53
Caspase
MEK
Bcl-2 Family
p38 MAPK
Mitophagy
Reactive Oxygen Species (ROS)
Apoptosis
Calcium Channel
|
Cardiovascular Disease
Infection
Neurological Disease
|
|
Polygalasaponin F is an orally active triterpenoid saponin monomer. Polygalasaponin F downregulates the expression of Bax, p53, caspase-3, NF-κB p65 and MEK1; restores and upregulates the expression of Bcl-2; activates the PI3K/Akt signaling pathway; inhibits the phosphorylation of p38 MAPK, nuclear translocation of NF-κB, TLR4-mediated signaling pathway, mitophagy (Mitophagy) and ROS production; enhances cell viability and suppresses apoptosis (Apoptosis). Polygalasaponin F maintains mitochondrial function, alleviates Ca 2+ overload, upregulates pCREB and BDNF, preserves cell viability and inhibits the release of inflammatory cytokines. Polygalasaponin F alleviates lung injury induced by influenza A H1N1 and cerebral ischemia-reperfusion injury. Polygalasaponin F is applicable to researches related to Parkinson's disease, cerebral ischemia, pneumonia induced by influenza A H1N1, stroke and Alzheimer's disease .
|
-
- HY-124057
-
|
|
nAChR
|
Neurological Disease
|
|
RO5126946 is a selective, orally active α7 nAChR allosteric potentiator with EC50 values of 0.06 μM (hα7 nAChR) and 770 nM (α7 nAChR), and it crosses the blood-brain barrier. RO5126946 enhances synaptic transmission and positively modulates GABA-ergic responses by increasing peak current, slowing current decay, and elevating the frequency of spontaneous inhibitory postsynaptic currents, without affecting the recovery of receptors from the desensitized state. RO5126946 not only enhances subthreshold nicotine effects and improves associative learning, but also does not interfere with the original pro-cognitive effects of nicotine. RO5126946 can be used to study cognitive impairments associated with diseases such as Alzheimer's disease and schizophrenia .
|
-
- HY-P2259
-
|
|
iGluR
HIV Integrase
Adenosine Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of AMPA receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction .
|
-
- HY-100658S
-
|
|
Isotope-Labeled Compounds
5-HT Receptor
Dopamine Receptor
|
Neurological Disease
|
|
Didesmethyl cariprazine-d8 is the deuterium labeled Didesmethyl cariprazine (HY-100658). Didesmethyl cariprazine is an orally active, BBB-permeable metabolite of Cariprazine (HY-14763). Didesmethyl cariprazine is a partial agonist at the D2 and D3 receptors, full agonist at the 5-HT1A receptor, and antagonist at the human 5-HT2B receptor (Ki: 1.41 nM (human D2L), 0.056 nM (human D3), 1.7 nM (human 5-HT1A), 0.52 nM (human 5-HT2B)). Didesmethyl cariprazine dose-dependently inhibits the spontaneous activity of rat midbrain dopaminergic neurons.
|
-
- HY-N6746S1
-
|
NSC 186-13C13
|
Isotope-Labeled Compounds
Apoptosis
Bacterial
Autophagy
|
Infection
Neurological Disease
Cancer
|
|
Citrinin- 13C13 (NSC 186- 13C13) is the 13C labeled Citrinin (HY-N6746). Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
|
-
- HY-168906
-
|
|
Bradykinin Receptor
PI3K
Akt
TNF Receptor
ERK
|
Neurological Disease
Inflammation/Immunology
|
|
BI-113823 is an orally active, blood-brain barrier-permeable bradykinin B1 receptor antagonist, with a Ki value of 5.3 nM for human receptors and 13.3 nM for rat receptors. BI-113823 reduces inflammation-induced mechanical hyperalgesia, as well as the mechanical sensitivity of peripheral afferent nerves and spinal nociceptive-specific neurons. BI-113823 alleviates liver fibrosis and portal hypertension, and improves survival in chronic liver disease models. BI-113823 inhibits the activities of monocytes, neutrophils and hepatic stellate cells, as well as the PI3K/Akt signaling pathway. BI-113823 can be used in research related to inflammatory pain, liver fibrosis and portal hypertension .
|
-
- HY-14604
-
|
SR57746A; SR57746 hydrochloride
|
5-HT Receptor
Dopamine Receptor
Trk Receptor
PKC
ERK
Akt
JNK
|
Neurological Disease
Metabolic Disease
|
|
Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ 35S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .
|
-
- HY-119820
-
|
SR57746A free base
|
Akt
Dopamine Receptor
Trk Receptor
5-HT Receptor
PKC
JNK
ERK
|
Neurological Disease
|
|
Xaliproden (SR57746) free base is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden free base activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden free base also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ 35S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden free base exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden free base also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden free base can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .
|
-
- HY-15691A
-
|
|
Opioid Receptor
mTOR
|
Neurological Disease
Metabolic Disease
|
|
PF-4455242 hydrochloride is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-4455242 hydrochloride blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-4455242 hydrochloride promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-4455242 hydrochloride attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-4455242 hydrochloride can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .
|
-
- HY-15691
-
|
|
Opioid Receptor
mTOR
|
Neurological Disease
Metabolic Disease
|
|
PF-04455242 is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-04455242 blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-04455242 promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-04455242 attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-04455242 can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .
|
-
- HY-110023
-
|
|
Serotonin Transporter
|
Neurological Disease
|
|
Zimelidine dihydrochloride is an orally active selective serotonin reuptake inhibitor. Zimelidine dihydrochloride competitively inhibits central 5-HT uptake and desensitizes 5-HT autoreceptors in dorsal raphe nucleus. Zimelidine dihydrochloride time-dependently modulates 5-HT neuronal firing and hippocampal CA3 responses. Zimelidine dihydrochloride strengthens central serotonergic neurotransmission and produces related behavioral changes. Zimelidine dihydrochloride exerts anxiolytic, analgesic, feeding-suppressive and tolerance-attenuating effects. Zimelidine dihydrochloride is used for the study of depressive disorders and analgesic tolerance .
|
-
- HY-100658R
-
|
|
5-HT Receptor
Reference Standards
Dopamine Receptor
|
Neurological Disease
|
|
Didesmethyl cariprazine (Standard) is the analytical standard of Didesmethyl cariprazine (HY-100658). This product is intended for research and analytical applications. Didesmethyl cariprazine is an orally active, BBB-permeable metabolite of Cariprazine (HY-14763). Didesmethyl cariprazine is a partial agonist at the D2 and D3 receptors, full agonist at the 5-HT1A receptor, and antagonist at the human 5-HT2B receptor (Ki: 1.41 nM (human D2L), 0.056 nM (human D3), 1.7 nM (human 5-HT1A), 0.52 nM (human 5-HT2B)). Didesmethyl cariprazine dose-dependently inhibits the spontaneous activity of rat midbrain dopaminergic neurons .
|
-
- HY-B1311
-
|
SKF-525A; U-5446; RP-5171
|
Cytochrome P450
Monoamine Oxidase
Bcl-2 Family
Survivin
PARP
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Proadifen (SKF-525A) hydrochloride is a non-competitive Cytochrome P450 inhibitor with an IC50 value of 19 μM. Proadifen hydrochloride reduces monoamine oxidase A (MAO-A) activity and reverses the antidepressantlike behavioral effect of Imipramine (HY-B1490A) and Desipramine (HY-B1272A) in rats. Proadifen hydrochloride also reduces N, N-dimethyltryptamine (DMT) metabolism in liver microsomes and inhibits N-demethylationand Acridone (HY-W007771) formation. Proadifen hydrochloride augments Lipopolysaccharide (LPS) (HY-D1056)-induced fever and exacerbates Prostaglandin E2 (PGE2) (HY-101952) levels in the rat. Proadifen hydrochloride is promising for research of metabolism-related deseases, ovarian carcinoma, inflammation and dopamine neurons-related deseases .
|
-
- HY-181348
-
|
|
HBV
|
Infection
|
|
HBV-IN-56 is an orally active HBsAg production inhibitor. HBV-IN-56 inhibits HBsAg production both in vitro and in vivo. HBV-IN-56 can be used for the research of chronic hepatitis B virus infection .
|
-
- HY-145607
-
-
- HY-14604R
-
|
SR57746A (Standard); SR57746 hydrochloride (Standard)
|
Reference Standards
Akt
Dopamine Receptor
Trk Receptor
5-HT Receptor
PKC
JNK
ERK
|
Neurological Disease
Cancer
|
|
Xaliproden (hydrochloride) (Standard) is the analytical standard of Xaliproden (hydrochloride). This product is intended for research and analytical applications. Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ 35S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .
|
-
- HY-183857
-
|
|
TRP Channel
|
Neurological Disease
|
|
DD-161515 is a TRPV1/VR1 inhibitor with an IC50 of 0.7 μM in rats. DD-161515 binds to an allosteric site of TRPV1 distinct from that of capsaicin, blocks channel opening, inhibits receptor-mediated calcium ion influx, reduces the excitability of peripheral sensory nerve fibers, and thereby inhibits nociception induced by heat and transmission of chemically induced pain signals. DD-161515 can be used in studies related to inflammatory pain .
|
-
- HY-N16499
-
|
|
Interleukin Related
GDNF Receptor
Trk Receptor
ERK
|
Neurological Disease
Inflammation/Immunology
|
|
Hericene A is an orally active aromatic hericene derivative. Hericene A exhibits anti-inflammatory and neurotrophic activities, and can found in the fruiting bodies of Hericium erinaceus. Hericene A inhibits the secretion of pro-inflammatory mediators. Hericene A promotes axonal growth, neurite branching, neurotrophic factor expression and downstream signal transduction. Hericene A can be used for the research of inflammatory and neurological diseases .
|
-
- HY-181662
-
|
|
MAP3K
|
Neurological Disease
|
|
DLK-IN-2 is a selective inhibitor of DLK and neuroprotective agent. DLK-IN-2 shows no significant inhibition against CYPs 3A4, 2D6 and 2C9. DLK-IN-2 inhibits acute axonal palmitoylation of DLK, blocks DLK-dependent pro-degenerative axon-to-soma retrograde signaling and suppresses c-Jun phosphorylation. DLK-IN-2 can be used for the mechanistic study of neurodegenerative diseases .
|
-
- HY-100604
-
|
|
γ-secretase
Amyloid-β
|
Neurological Disease
|
|
JNJ-40418677 is an orally active modulator of γ-secretase, can cross the blood-brain barrier. JNJ-40418677 inhibits Aβ42 and NS2B-NS3 protease, with IC50s of 200 nM and 3.9 μM, respectively. JNJ-40418677 displays good biological tolerance, can be use for Alzheimer’s disease research .
|
-
- HY-B1311R
-
|
SKF-525A (Standard); U-5446 (Standard); RP-5171 (Standard)
|
Reference Standards
Cytochrome P450
Monoamine Oxidase
Bcl-2 Family
Survivin
PARP
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Proadifen (hydrochloride) (Standard) is the analytical standard of Proadifen (hydrochloride). This product is intended for research and analytical applications. Proadifen (SKF-525A) hydrochloride is a non-competitive Cytochrome P450 inhibitor with an IC50 value of 19 μM. Proadifen hydrochloride reduces monoamine oxidase A (MAO-A) activity and reverses the antidepressantlike behavioral effect of Imipramine (HY-B1490A) and Desipramine (HY-B1272A) in rats. Proadifen hydrochloride also reduces N, N-dimethyltryptamine (DMT) metabolism in liver microsomes and inhibits N-demethylationand Acridone (HY-W007771) formation. Proadifen hydrochloride augments Lipopolysaccharide (LPS) (HY-D1056)-induced fever and exacerbates Prostaglandin E2 (PGE2) (HY-101952) levels in the rat. Proadifen hydrochloride is promising for research of metabolism-related deseases, ovarian carcinoma, inflammation and dopamine neurons-related deseases [4] .
|
-
- HY-W392413
-
|
|
Drug Derivative
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Glutathione monoethyl ester is a glutathione derivative that can be transported into cells and hydrolyzed into glutathione. Glutathione monoethyl ester downregulates the gene expression of TEN1 and CTC1 while upregulating TERT expression. Glutathione monoethyl ester enhances telomerase activity, promotes proliferation and differentiation in aged bone marrow stromal cells, while elevating glutathione levels and reducing oxidative stress, protein aggregation and cell death in motor neuronal cells. Glutathione monoethyl ester confers broad multi-organ protection against cerebral ischemia, renal injury, liver damage, and pancreatitis. Glutathione monoethyl ester can be used for the research of amyotrophic lateral sclerosis, stroke, acute renal failure, liver injury, and acute pancreatitis .
|
-
- HY-108592
-
|
|
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
UCL 2077 is a potassium channel and slow afterhyperpolarization (sAHP) inhibitor. UCL 2077 selectively blocks sAHP channels without affecting L-type Ca 2+ currents. UCL 2077 blocks KCNQ1- and KCNQ2-containing K + channels, decreases erg current amplitude, increases erg deactivation rate. UCL 2077 can be used for the research of hippocampus-dependent memory retrieval deficit and cardiac arrhythmias .
|
-
- HY-175340
-
|
|
Potassium Channel
TSPO
|
Neurological Disease
|
|
Kv7.2/Kv7.3 activator-3 (GRT-X) is an orally active Kv7.2/Kv7.3 and TSPO activator. Kv7.2/Kv7.3 activator-3 activates Kv7.2/Kv7.3, Kv7.4, and Kv7.5 with EC50 values of 0.37, 2.06, and 0.75 μM, respectively, and binds to TSPO with Ki values of 0.07 μM (rat membrane) and 4.60 μM (human U-118 MG cells). Kv7.2/Kv7.3 activator-3 prevents motor neuron degeneration in mice and humans conditioned by ALS/FTD astrocytes. Kv7.2/Kv7.3 activator-3 stimulates dorsal root ganglion axonal growth through TSPO and Kv7.2/3 activation. Kv7.2/Kv7.3 activator-3 has anti-epileptic effects in epileptic seizure models. Kv7.2/Kv7.3 activator-3 reduces pain hypersensitivity in patients with diabetic neuropathy, promotes neuronal survival and regeneration after cervical neuropathy in rats, and accelerates the recovery of normal function of sensory and motor neurons .
|
-
- HY-N6043
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
Bacterial
SARS-CoV
Estrogen Receptor/ERR
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
|
-
- HY-N2183
-
|
Quercetin 3-O-sophoroside
|
SARS-CoV
|
Infection
Neurological Disease
|
|
Baimaside (Quercetin 3-O-sophoroside) is a flavonoid cholinergic function modulator that binds to SARS-CoV-2-related targets. Baimaside regulates the expression of cholinergic system-related proteins and acetylcholine levels, improves scopolamine-induced learning and memory impairment, protects hippocampal neurons, inhibits pollen protein fluorescence, and protects pollen DNA. Its biosynthesis is regulated by multiple enzymes. Baimaside is completely absorbed in rats, undergoes phase Ⅱ metabolism and gut microbiota decomposition, and inhibits the invasion and proliferation of SARS-CoV-2 and its variants, making it suitable for research related to Alzheimer's disease and COVID-19 .
|
-
- HY-P10638
-
|
|
CaMK
|
Cardiovascular Disease
Neurological Disease
|
|
TAT-CN21 is a potent CaMKII inhibitor with an IC50 of 77.2 nM. TAT-CN21 inhibits both calcium/calmodulin-dependent and autonomously activated CaMKII, blocks glutamate-induced translocation of CaMK IIα, and reverses the enhanced phosphorylation of CaMKII at Thr286 following excitotoxic injury. TAT-CN21 shows application potential in studies related to ischemic stroke by reducing neuronal excitotoxicity and exacerbating pre-existing long-term neuronal death prior to injury. TAT-CN21 improves definitive behaviors in rats with residual nerve injury without altering indicators such as mechanical/thermal hyperalgesia or spatial memory. TAT-CN21 can also be used in studies related to neuropathic pain .
|
-
- HY-182940
-
|
|
Toll-like Receptor (TLR)
|
Neurological Disease
|
|
SARM1-IN-10 is an orally active SARM1 inhibitor with a pIC50 of 7.1 and a pKd of 8.3. As a base-exchange inhibitor, SARM1-IN-10 forms a NAD + adduct at the active site of the TIR domain of SARM1, blocks enzymatic function, and induces a unique rotameric state of W662 at the catalytic site of SARM1. SARM1-IN-10 acts as a paradoxical neurodegeneration inducer at low doses and an inhibitor at high doses, and it can exacerbate or protect against SARM1-mediated neurodegeneration depending on concentration. SARM1-IN-10 can be used in studies of peripheral neurodegeneration .
|
-
- HY-117545
-
|
|
RAR/RXR
|
Cancer
|
|
LE-540 is a selective retinoic acid receptor antagonist for RARβ (Ki=0.22 μM). LE-540 shows potential for use in cancer research, particularly for breast cancer and lung cancer .
|
-
- HY-D1631
-
-
- HY-N2125
-
|
|
5-HT Receptor
iGluR
Caspase
Interleukin Related
TNF Receptor
SOD
NF-κB
|
Neurological Disease
Inflammation/Immunology
|
|
Parishin C is a brain-penetrant major bioactive component found in Gastrodia elata Blume. Parishin C is a 5-HT1A receptor agonist with an EC50 of 34 nM. Parishin C has antipsychotic and neuroprotective effects. Parishin C protects against Aβ-induced long-term potentiation damage and NMDA receptor current impairment. Parishin C reduces oxidative stress, pro-inflammatory cytokine levels, caspase activity, brain water content, and cerebral infarct volume; increases antioxidant enzyme activity and BDNF levels; improves nerve function and histopathological brain damage. Parishin C attenuates phencyclidine-induced immobility time increases, sociability deficits, and visual recognition memory impairment. Parishin C can be used for the research of ischemic stroke, Alzheimer's disease, and schizophrenia-like psychosis .
|
-
- HY-17355B
-
|
(R)-Pramipexole; R-(+)-Pramipexole; KNS-760704
|
PINK1/Parkin
Glutathione Peroxidase
Sodium Channel
ATP Synthase
NOD-like Receptor (NLR)
Mitophagy
Ferroptosis
Autophagy
Apoptosis
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Dexpramipexole ((R)-Pramipexole) is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the Nav1.8 sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more .
|
-
- HY-Y1269D
-
|
Salmiac, for molecular biology
|
TGF-beta/Smad
Apoptosis
Chloride Channel
|
Neurological Disease
Cancer
|
|
Ammonium chloride (Salmiac), for molecular biology is an inhibitor of Slc26a4 and SMAD2. Ammonium chloride, for molecular biology reduces the protein expression level of Slc26a4 in lung tissue, and attenuates ozone-induced increases in proinflammatory cytokines, inflammatory cells, pulmonary resistance, goblet cell hyperplasia, peribronchial inflammation and thiocyanate levels in mouse tissues and bronchoalveolar lavage fluid. Ammonium chloride, for molecular biology decreases the level of phosphorylated SMAD2, inhibits autophagy by reducing autophagy-related proteins, and enhances Cisplatin (HY-17394)-induced cancer cell apoptosis and DNA double-strand breaks. Ammonium chloride, for molecular biology also inhibits the TCA cycle, reduces ATP production, increases glucose utilization, regulates the levels of lactic acid, glutamic acid and ATP, and induces morphological degeneration of neuroblastoma cells. Ammonium chloride, for molecular biology can be used in studies related to ozone-induced airway injury, hepatocellular carcinoma, human cervical cancer, hepatic encephalopathy, Reye syndrome, epilepsy and neurodegenerative diseases .
|
-
- HY-N0663
-
|
|
Mitochondrial Metabolism
Cyclophilin
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Talatisamine is an orally active cyclophilin D activator isolated from the roots of Aconitum carmichaeli Debx. Talatisamine exerts biological functions by activating cyclophilin D, inhibiting Ca 2+-dependent opening of the mitochondrial permeability transition pore (mPTP) (IC50=78 μM), and blocking delayed rectifier K + channels (IC50=146 μM). Talatisamine possesses both antioxidant and membrane-stabilizing properties, effectively inhibits lipid peroxidation and protects mitochondrial membrane function. Talatisamine exhibits multiple activities including antiarrhythmic, hypotensive, anti-inflammatory, anticancer and neuroprotective effects. Talatisamine finds applications in the research of ischemic diseases, rheumatoid arthritis, inflammation-related diseases and Alzheimer's disease .
|
-
- HY-121362
-
|
|
Bacterial
Endogenous Metabolite
TrxR
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Evernic Acid is an orally active thioredoxin reductase 1 (TrxR1) inhibitor and antiproliferative agent. Evernic Acid inhibits the proliferation and migration of human breast cancer cells. Evernic Acid blocks the NF-κB pathway by inhibiting p65 nuclear translocation and IκBα phosphorylation, thereby suppressing downstream inflammatory mediators. Evernic Acid acts as an antioxidant, anti-inflammatory agent and neuroprotective agent, protects neurons from cell death, mitochondrial dysfunction and oxidative stress damage, reduces astrocyte activation, and ameliorates dopaminergic neuron loss and neuroinflammation. Evernic Acid inhibits enoyl reductases FabI and FabZ of Plasmodium falciparum. Evernic Acid downregulates the expression of lasB and rhlA genes in Pseudomonas aeruginosa, inhibits quorum sensing and biofilm formation, and exerts antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and fungi. Evernic Acid is applicable to research related to breast cancer, Parkinson's disease, bacterial infections and fungal infections .
|
-
- HY-107581
-
MK-1903
1 Publications Verification
|
GPR109A
MMP
|
Metabolic Disease
Inflammation/Immunology
|
|
MK-1903 is an orally active full agonist of GPR109a/HCAR2, with an EC50 of 12.9 nM. MK-1903 activates antilipolytic and vasodilatory pathways, reduces plasma free fatty acid levels, and induces skin flushing. MK-1903 stimulates the expression of HCAR2 protein and regulates the inflammatory response of microglia. MK-1903 prevents the enhanced firing activity of spinal nociceptive neurons. MK-1903 triggers the release of MMP-9 and the formation of NET. MK-1903 can be used in the research of dyslipidemia and neuroinflammation-based central nervous system diseases .
|
-
- HY-P1341
-
|
Orexin A (17-33) (human, mouse, rat, bovine)
|
Orexin Receptor (OX Receptor)
Sigma Receptor
Phospholipase
|
Neurological Disease
|
|
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC50=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca 2+ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .
|
-
- HY-P1426
-
|
|
Potassium Channel
|
Neurological Disease
|
|
AmmTX3 is a peptide toxin identified from the venom of the scorpion Androctonus mauretanicus. AmmTX3 is a highly specific blocker of Kv4 channels, which selectively and almost completely blocks transient A-type K + currents with a Ki of 131 nM. AmmTX3 induces epileptiform behaviors and causes death in mice receiving intracerebroventricular injection. AmmTX3 increases the excitability of dentate gyrus granule cells, reduces GABAergic inhibition, enhances and stabilizes the EPSP-spike component of long-term potentiation, and impairs reference memory. AmmTX3 can be used in research related to pain, epilepsy, and autism spectrum disorder .
|
-
- HY-Y0669
-
-
- HY-112847B
-
|
(E/Z)-Sulfo-N-succinimidyl oleate sodium
|
Transmembrane Glycoprotein
Mitochondrial Metabolism
Drug Isomer
|
Inflammation/Immunology
|
|
(E/Z)-Sulfosuccinimidyl oleate sodium is the racemate of (E)-Sulfosuccinimidyl oleate sodium and (Z)-Sulfosuccinimidyl oleate sodium. Sulfosuccinimidyl oleate sodium (Sulfo-N-succinimidyl oleate sodium) is a long-chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate sodium is a potent and irreversible inhibitor of the mitochondrial respiratory chain. Sulfosuccinimidyl oleate sodium binds to the CD36 receptor on the surface of microglial cells. Sulfosuccinimidyl oleate sodium exhibits anti-inflammatory effects .
|
-
- HY-N0909
-
|
20(S)-Notoginsenoside R2; Ginsenoside Ng-R2
|
Apoptosis
MEK
ERK
Reactive Oxygen Species (ROS)
Caspase
COX
β-catenin
Src
MDM-2/p53
JAK
STAT
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active notoginsenoside . Notoginsenoside R2 activates P90RSK and Nrf2 via the MEK1/2-ERK1/2 pathway to inhibit 6-OHDA-induced apoptotic damage in nerve cells. Notoginsenoside R2 upregulates SOX8/β-catenin by reducing miR-27a, thereby suppressing Aβ25-35-induced neuronal apoptosis and inflammatory responses . Notoginsenoside R2 alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src. Notoginsenoside R2 alleviates hepatic fibrosis by inducing hepatic stellate cell senescence and inhibiting the inflammatory microenvironment via JAK/STAT3 suppression . Notoginsenoside R2 can be used in research related to Parkinson's disease, Alzheimer's disease, diabetic nephropathy and hepatic fibrosis .
|
-
- HY-121675A
-
|
BOL-148 D-Tartrate; Bromolysergide D-Tartrate
|
5-HT Receptor
G protein-coupled Bile Acid Receptor 1
|
Neurological Disease
|
|
2-Bromo-LSD D-Tartrate (BOL-148 D-Tartrate) is a blood-brain barrier-permeable 5-HT2A partial agonist and competitive partial antagonist. 2-Bromo-LSD D-Tartrate acts as both a potent partial agonist (with an EC50 of 0.81 nM for Gq dissociation) and a potent partial antagonist (with a KB of 0.18 nM for Gq dissociation) at the 5-HT2A receptor. 2-Bromo-LSD D-Tartrate exhibits partial agonist activity at multiple aminergic GPCRs, including 5-HT2A. 2-Bromo-LSD D-Tartrate lacks 5-HT2B agonist activity. 2-Bromo-LSD D-Tartrate induces dendritogenesis and spinogenesis. 2-Bromo-LSD D-Tartrate reverses the behavioral effects of chronic stress and increases active coping behaviors in mice .
|
-
- HY-186073
-
|
|
HDAC
|
Neurological Disease
|
|
HDAC1 activator-1 is a specific HDAC1 activator with orally activity, exerting no significant effects on other HDAC family members. HDAC1 activator-1 exhibits neuroprotective activity, ameliorates cognitive and motor function deficits by reducing neuronal loss and gliosis. HDAC1 activator-1 specifically activates HDAC1 in SH-SY5Y cells and exerts regulatory effects on aberrant cell cycle and DNA damage. HDAC1 activator-1 can be used for the research of TDP-43 proteinopat1-related neurodegenerative diseases including Amyotrophic Lateral Sclerosis (ALS) and cerebral ischemia-related neurological injury .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D1631
-
|
|
Fluorescent Dyes
|
|
Calcium Green-5N AM is a Ca 2+-sensitive fluorescent probe (Kd = 14 μM). Calcium Green-5N AM shows enhanced fluorescence intensity upon binding to Ca 2+, and it can monitor free Ca 2+ in neurons .
|
-
- HY-D2481
-
|
APG-2 TMA
|
Fluorescent Dyes
|
|
Asante potassium green-2 (APG-2) TMA is a cell-impermeable K + (potassium ion) fluorescent indicator that produces a fluorescent response to changes in extracellular potassium ion concentration. Its excitation/emission maxima are 525/545 nm , respectively.
|
-
- HY-D3394
-
|
|
Fluorescent Dyes
|
|
SGC5 is a fluorescence enhancer and membrane dissociator with millisecond-scale membrane dissociation kinetics, with an emission spectrum of 500-650 nm. SGC5 produces strong fluorescence upon binding to lipid membranes, exhibits fast partitioning dissociation kinetics at higher temperatures, and is unaffected by pH or cholesterol. SGC5 does not belong to the FM dye family and shows the highest membrane-bound fluorescence intensity among the tested styryl/FM dyes. SGC5 can be used to study synaptic vesicle cycling in neurons .
|
| Cat. No. |
Product Name |
Type |
-
- HY-Y0669
-
|
|
Biochemical Assay Reagents
|
|
Pipecolic acid is an orally bioavailable, blood-brain barrier-permeable metabolite of lysine with antioxidant, inhibitor, and inducer activity. Pipecolic acid modulates the YAP-GPX4 signaling pathway, reduces retinal vascular tube formation, and mitigates ferroptosis. Pipecolic acid potentiates voltage-sensitive Ca 2+ channel currents and induces neuronal apoptosis. Pipecolic acid can be used for the research of diabetic retinopathy .
|
-
- HY-W002438
-
|
|
Biochemical Assay Reagents
|
|
6-Hydroxyindole is an orally active, endogenous long-acting OATP1B1 inhibitor. 6-Hydroxyindole does not alter the cell surface expression or subcellular localization of OATP1B1. 6-Hydroxyindole protects cells against Ferroptosis. 6-Hydroxyindole possesses intrinsic radical-trapping antioxidant activity. 6-Hydroxyindole serves as a component of oxidative hair dyes. 6-Hydroxyindole can be used in research related to renal failure and neurodegenerative diseases .
|
-
- HY-Y1269D
-
|
Salmiac, for molecular biology
|
Biochemical Assay Reagents
|
|
Ammonium chloride (Salmiac), for molecular biology is an inhibitor of Slc26a4 and SMAD2. Ammonium chloride, for molecular biology reduces the protein expression level of Slc26a4 in lung tissue, and attenuates ozone-induced increases in proinflammatory cytokines, inflammatory cells, pulmonary resistance, goblet cell hyperplasia, peribronchial inflammation and thiocyanate levels in mouse tissues and bronchoalveolar lavage fluid. Ammonium chloride, for molecular biology decreases the level of phosphorylated SMAD2, inhibits autophagy by reducing autophagy-related proteins, and enhances Cisplatin (HY-17394)-induced cancer cell apoptosis and DNA double-strand breaks. Ammonium chloride, for molecular biology also inhibits the TCA cycle, reduces ATP production, increases glucose utilization, regulates the levels of lactic acid, glutamic acid and ATP, and induces morphological degeneration of neuroblastoma cells. Ammonium chloride, for molecular biology can be used in studies related to ozone-induced airway injury, hepatocellular carcinoma, human cervical cancer, hepatic encephalopathy, Reye syndrome, epilepsy and neurodegenerative diseases .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1944
-
Apelin-13
Maximum Cited Publications
10 Publications Verification
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
Metabolic Disease
|
|
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .
|
-
- HY-P0198
-
-
- HY-P1944A
-
Apelin-13 TFA
Maximum Cited Publications
10 Publications Verification
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
Metabolic Disease
|
|
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .
|
-
- HY-P5912
-
|
|
iGluR
Calcium Channel
|
Neurological Disease
|
|
GluN1 (356-385) is a polypeptide targeting NMDAR GluN1. GluN1 (356-385) induces the production of autoantibodies, which reduce the density of cell surface NMDAR clusters, impair long-term potentiation, and decrease NMDAR-mediated Ca 2+ influx. As an immunogen, GluN1 (356-385) induces symptoms similar to anti-NMDAR encephalitis, including memory loss, in mice. GluN1 (356-385) can be used to establish a mouse model that mimics the pathogenesis of anti-NMDAR encephalitis. GluN1 (356-385) is applicable to research related to anti-NMDAR encephalitis .
|
-
- HY-P1248
-
|
NPFF
|
Neuropeptide FF Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Neuropeptide FF (NPFF), an octapeptide belonging to the RF-amide family of peptides, is a NPFF1 and NPFF2 receptors agonist with Ki values of 2.82 nM and 0.21 nM, respectively. Neuropeptide FF induces abstinence syndrome, exerts antiopioid and analgesic effects, releases via calcium-dependent mechanisms from rat spinal cord, regulates memory, autonomic function, and neuroendocrine function, modulates pain and opioid antinociception, reduces food intake, stimulates water intake, alters cardiovascular parameters, and shows differential activity in hypothalamic paraventricular nucleus neurons. Neuropeptide FF is present in mammalian central nervous system and periphery, with NPFF-immunoreactivity increases in rat cerebrospinal fluid during opiate tolerance, and its NPFF gene and NPFF-R2 gene are up-regulated in rat spinal cord and dorsal root ganglia during peripheral inflammation. Neuropeptide FF can be used for the research of opioid tolerance, morphine-induced analgesia, abstinence syndrome, pain, hypertension, nociception, inflammatory pain, and neuropathic pain .
|
-
- HY-P10638
-
|
|
CaMK
|
Cardiovascular Disease
Neurological Disease
|
|
TAT-CN21 is a potent CaMKII inhibitor with an IC50 of 77.2 nM. TAT-CN21 inhibits both calcium/calmodulin-dependent and autonomously activated CaMKII, blocks glutamate-induced translocation of CaMK IIα, and reverses the enhanced phosphorylation of CaMKII at Thr286 following excitotoxic injury. TAT-CN21 shows application potential in studies related to ischemic stroke by reducing neuronal excitotoxicity and exacerbating pre-existing long-term neuronal death prior to injury. TAT-CN21 improves definitive behaviors in rats with residual nerve injury without altering indicators such as mechanical/thermal hyperalgesia or spatial memory. TAT-CN21 can also be used in studies related to neuropathic pain .
|
-
- HY-P1080
-
|
|
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
ω-Agatoxin IVA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50 values of 2 nM and 90 nM. ω-Agatoxin IVA inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA inhibits Capsaicin (HY-10448)-induced CGRP release and vasodilation. ω-Agatoxin IVA can be used for the research of neurological and cardiovascular disease .
|
-
- HY-P2543
-
|
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Neuropeptide Y (3-36) (human, rat) is a neuropeptide Y fragment derived from humans or rats. Neuropeptide Y is an extremely abundant neurotransmitter in central and peripheral neurons, and it participates in the regulation of psychomotor activity, circadian rhythm, feeding behavior and cardiovascular function. Neuropeptide Y (3-36) (human, rat) can serve as a substrate to be sequentially degraded from its N-terminus by AfuS28, and it requires binding to AfuS28 and SedB to be decomposed into amino acids, dipeptides and tripeptides [1] [2].
|
-
- HY-P1205A
-
|
Melanin-concentrating hormone(human, mouse, rat) TFA
|
MCHR1 (GPR24)
|
Neurological Disease
Metabolic Disease
|
|
MCH (human, mouse, rat) TFA is a cyclic neuropeptide mainly synthesized by neurons in the lateral hypothalamic area. MCH (human, mouse, rat) TFA also serves as an endogenous ligand for the melanin-concentrating hormone receptor (MHC receptor), with a binding IC50 of 0.3 nM and 1.5 nM for human MCH-1R and MCH-2R, respectively; its functional EC50 values are 3.9 nM and 88.7 nM. MCH (human, mouse, rat) TFA acts not only as an orexigenic signal but also as a key integrating and regulatory hormone for energy homeostasis and sleep-wake cycles. MCH (human, mouse, rat) TFA can be used in studies related to obesity, sleep disorders, and other associated conditions .
|
-
- HY-P2259
-
|
|
iGluR
HIV Integrase
Adenosine Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of AMPA receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction .
|
-
- HY-P0198A
-
-
- HY-P1341
-
|
Orexin A (17-33) (human, mouse, rat, bovine)
|
Orexin Receptor (OX Receptor)
Sigma Receptor
Phospholipase
|
Neurological Disease
|
|
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC50=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca 2+ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .
|
-
- HY-P1387
-
|
|
Amyloid-β
Apoptosis
|
Neurological Disease
|
|
β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases 45Ca 2+ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease .
|
-
- HY-P3071
-
|
Stichodactyla helianthus neurotoxin
|
Potassium Channel
|
Neurological Disease
Inflammation/Immunology
|
|
ShK toxin blocks voltage-dependent potassium channel (Kv1.3 channel). ShK toxin can be isolated from the whole body extract of the Caribbean sea anemone (Stichodactylu helianthus). ShK toxin competes with dendrotoxin I and α-dendrotoxin for binding to synaptosomal membranes of rat brain, facilitates acetylcholine release. ShK toxin suppresses K+ currents in cultured rat dorsal root ganglion neurons. ShK toxin also inhibits T lymphocyte proliferation .
|
-
- HY-P1205
-
|
Melanin-concentrating hormone(human, mouse, rat)
|
MCHR1 (GPR24)
|
Neurological Disease
Metabolic Disease
|
|
MCH (human, mouse, rat) is a cyclic neuropeptide mainly synthesized by neurons in the lateral hypothalamic area. MCH (human, mouse, rat) also serves as an endogenous ligand for the melanin-concentrating hormone receptor (MHC receptor), with a binding IC50 of 0.3 nM and 1.5 nM for human MCH-1R and MCH-2R, respectively; its functional EC50 values are 3.9 nM and 88.7 nM. MCH (human, mouse, rat) acts not only as an orexigenic signal but also as a key integrating and regulatory hormone for energy homeostasis and sleep-wake cycles. MCH (human, mouse, rat) can be used in studies related to obesity, sleep disorders, and other associated conditions .
|
-
- HY-P10360
-
|
|
α-synuclein
|
Neurological Disease
|
|
Tat-βsyn-degron is an α-synuclein knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders .
|
-
- HY-P5118A
-
|
|
Peptides
|
Neurological Disease
|
|
Tat-peptide 190-208 TFA is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 TFA increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 TFA likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 TFA can be used for ischemic protection during endovascular repair for intracranial aneurysms .
|
-
- HY-P3528
-
|
|
Caspase
Apoptosis
|
Neurological Disease
|
|
GPR is a three amino acid peptide. GPR can rescue cultured rat hippocampal neurons from Aβ-induced neuronal death by inhibiting caspase-3/p53 dependent apoptosis. GPR can be used for the research of Alzheimer's disease (AD).
|
-
- HY-P3071A
-
|
Stichodactyla helianthus neurotoxin TFA
|
Potassium Channel
|
Neurological Disease
Inflammation/Immunology
|
|
ShK toxin TFA (Stichodactyla helianthus neurotoxin TFA) is a neurotoxin. ShK toxin TFA blocks voltage-dependent potassium channel (Kv1.3 channel). ShK toxin TFA can be isolated from the whole body extract of the Caribbean sea anemone (Stichodactylu helianthus). ShK toxin TFA competes with dendrotoxin I and α-dendrotoxin for binding to synaptosomal membranes of rat brain, facilitates acetylcholine release. ShK toxin TFA suppresses K + currents in cultured rat dorsal root ganglion neurons. ShK toxin TFA also inhibits T lymphocyte proliferation .
|
-
- HY-P1426
-
|
|
Potassium Channel
|
Neurological Disease
|
|
AmmTX3 is a peptide toxin identified from the venom of the scorpion Androctonus mauretanicus. AmmTX3 is a highly specific blocker of Kv4 channels, which selectively and almost completely blocks transient A-type K + currents with a Ki of 131 nM. AmmTX3 induces epileptiform behaviors and causes death in mice receiving intracerebroventricular injection. AmmTX3 increases the excitability of dentate gyrus granule cells, reduces GABAergic inhibition, enhances and stabilizes the EPSP-spike component of long-term potentiation, and impairs reference memory. AmmTX3 can be used in research related to pain, epilepsy, and autism spectrum disorder .
|
-
- HY-P1474
-
|
Amyloid β-Protein (22-35)
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35), the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
- HY-P1474A
-
|
Amyloid β-Protein (22-35) TFA
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
- HY-P5179
-
|
HWTX-I
|
Calcium Channel
Sodium Channel
|
Neurological Disease
|
|
Huwentoxin I (HWTX-I) is a peptide toxin that inhibits voltage-gated sodium channels and N-type calcium channels. Huwentoxin I inhibits sodium channels in rat hippocampus and cockroach dorsal unpaired median (DUM) neurons with IC50 values of 66.1 and 4.80 nM, respectively .
|
-
- HY-P5773
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Jingzhaotoxin-34, a 35-residue polypeptide, is a neurotoxin. Jingzhaotoxin-34 inhibits tetrodotoxin-sensitive (TTX-S) sodium currents (IC50 of ~85 nM) while having no significant effects on tetrodotoxin-resistant (TTX-R) sodium currents on rat dorsal root ganglion neurons .
|
-
- HY-P5180
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Jingzhaotoxin-V is a peptide that inhibits potassium currents in Xenopus laevis oocytes with an IC50 value of 604.2 nM. Jingzhaotoxin-V also inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive sodium currents in rat dorsal root ganglion neurons with IC50 values of 27.6 and 30.2 nM, respectively .
|
-
- HY-P0198B
-
-
- HY-P5770
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Jingzhaotoxin-V, a 29-residue polypeptide, is derived from the venom of the spider Chilobrachys jingzhao. Jingzhaotoxin-V inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive sodium currents in rat dorsal root ganglion neurons with IC50 values of 27.6 nM and 30.2 nM, respectively. Jingzhaotoxin-V also inhibits Kv4.2 potassium currents expressed in Xenpus Laevis oocytes (IC50 of 604.2 nM) .
|
-
- HY-P5119
-
|
|
Peptides
|
Neurological Disease
|
|
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 190-208 (HY-P5118), as Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron .
|
-
- HY-P5782
-
|
|
Sodium Channel
|
Neurological Disease
|
|
δ-Theraphotoxin-Hm1a toxin is a selective Nav1.1 activator. δ-Theraphotoxin-Hm1a toxin elicits pain and touch sensitivity. δ-Theraphotoxin-Hm1a toxin can be used for the research of irritable bowel syndrome .
|
-
- HY-P5118
-
|
|
Peptides
|
Neurological Disease
|
|
Tat-peptide 190-208 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 can be used for ischemic protection during endovascular repair for intracranial aneurysms .
|
-
- HY-182539
-
|
|
CGRP Receptor
|
Others
Neurological Disease
|
|
DD04107 is a neuronal exocytosis inhibitor with a rat Syt1-C2B domain binding Ka of 2.4 μM. DD04107 interferes with synaptobrevin-syntaxin-SNAP-25 complex formation and Syt1-SNARE complex interaction to block α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons. DD04107 blocks inflammatory ion channel recruitment to nociceptor plasma membranes. DD04107 can be used for the research of chronic inflammatory pain, neuropathic pain, osteosarcoma pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, inflammatory pain .
|
-
- HY-P5119A
-
|
|
Peptides
|
Neurological Disease
|
|
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 168-189 TFA (HY-P5118A), as Tat-peptide 168-189 TFA increases axon growth and increases the number of neurites per neuron .
|
-
- HY-P1278B
-
|
|
Neurokinin Receptor
|
Neurological Disease
Endocrinology
|
|
GR 64349 acetate is a selective neurokinin 2 (NK2) receptor agonist. GR 64349 acetate selectively activates the NK-2 receptor subtype. GR 64349 acetate activates tonic and rhythmic bladder contractions of the micturition reflex. GR 64349 acetate does not inhibit rhythmic bladder contraction activation induced by normal saline. GR 64349 acetate induces inward currents .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P991815
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD90.1 Antibody (OX-7) reacts with the mouse and rat CD90.1. CD90 is present on a variety of cell types in murine and rat, including lymphatic vessels, T cells, neurons and fibroblasts. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
-
- HY-P992426
-
|
|
Tau Protein
|
Neurological Disease
|
|
NS101 is an anti-FAM19A5 antibody with an IC50 of 0.2 nM and a Kd of 111 pM, as well as blood-brain barrier permeability. NS101 binds to key amino acid residues of FAM19A5, thereby blocking the interaction of LRRC4B and disrupting the FAM19A5-LRRC4B complex. NS101 increases the dendritic spine density in hippocampal neurons and the prefrontal cortex, normalizes the dendritic spine elimination rate, elevates the frequencies of mEPSC and fEPSP, and promotes the transport of brain-derived FAM19A5 into the peripheral circulation. NS101 improves cognitive function in mouse models of Alzheimer's disease. NS101 can be used for research on Alzheimer's disease. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-W004260
-
-
-
- HY-N2183
-
-
-
- HY-N6746
-
-
-
- HY-N0663
-
|
|
Alkaloids
Structural Classification
Pyrrole Alkaloids
Ranunculaceae
Aconitum carmichaeli Debx.
Plants
Source Classification
|
Mitochondrial Metabolism
Cyclophilin
Potassium Channel
|
Talatisamine is an orally active cyclophilin D activator isolated from the roots of Aconitum carmichaeli Debx. Talatisamine exerts biological functions by activating cyclophilin D, inhibiting Ca 2+-dependent opening of the mitochondrial permeability transition pore (mPTP) (IC50=78 μM), and blocking delayed rectifier K + channels (IC50=146 μM). Talatisamine possesses both antioxidant and membrane-stabilizing properties, effectively inhibits lipid peroxidation and protects mitochondrial membrane function. Talatisamine exhibits multiple activities including antiarrhythmic, hypotensive, anti-inflammatory, anticancer and neuroprotective effects. Talatisamine finds applications in the research of ischemic diseases, rheumatoid arthritis, inflammation-related diseases and Alzheimer's disease .
|
-
-
- HY-N0061
-
-
-
- HY-121362
-
|
|
Structural Classification
other families
Classification of Application Fields
Ketones, Aldehydes, Acids
Plants
Inflammation/Immunology
Disease Research Fields
Source Classification
|
Bacterial
Endogenous Metabolite
TrxR
|
|
Evernic Acid is an orally active thioredoxin reductase 1 (TrxR1) inhibitor and antiproliferative agent. Evernic Acid inhibits the proliferation and migration of human breast cancer cells. Evernic Acid blocks the NF-κB pathway by inhibiting p65 nuclear translocation and IκBα phosphorylation, thereby suppressing downstream inflammatory mediators. Evernic Acid acts as an antioxidant, anti-inflammatory agent and neuroprotective agent, protects neurons from cell death, mitochondrial dysfunction and oxidative stress damage, reduces astrocyte activation, and ameliorates dopaminergic neuron loss and neuroinflammation. Evernic Acid inhibits enoyl reductases FabI and FabZ of Plasmodium falciparum. Evernic Acid downregulates the expression of lasB and rhlA genes in Pseudomonas aeruginosa, inhibits quorum sensing and biofilm formation, and exerts antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and fungi. Evernic Acid is applicable to research related to breast cancer, Parkinson's disease, bacterial infections and fungal infections .
|
-
-
- HY-N0392
-
|
|
Triterpenes
Structural Classification
Classification of Application Fields
Terpenoids
Polygalaceae
Polygala japonica Houtt.
Plants
Inflammation/Immunology
Disease Research Fields
Source Classification
|
Toll-like Receptor (TLR)
PI3K
Akt
NF-κB
MDM-2/p53
Caspase
MEK
Bcl-2 Family
p38 MAPK
Mitophagy
Reactive Oxygen Species (ROS)
Apoptosis
Calcium Channel
|
|
Polygalasaponin F is an orally active triterpenoid saponin monomer. Polygalasaponin F downregulates the expression of Bax, p53, caspase-3, NF-κB p65 and MEK1; restores and upregulates the expression of Bcl-2; activates the PI3K/Akt signaling pathway; inhibits the phosphorylation of p38 MAPK, nuclear translocation of NF-κB, TLR4-mediated signaling pathway, mitophagy (Mitophagy) and ROS production; enhances cell viability and suppresses apoptosis (Apoptosis). Polygalasaponin F maintains mitochondrial function, alleviates Ca 2+ overload, upregulates pCREB and BDNF, preserves cell viability and inhibits the release of inflammatory cytokines. Polygalasaponin F alleviates lung injury induced by influenza A H1N1 and cerebral ischemia-reperfusion injury. Polygalasaponin F is applicable to researches related to Parkinson's disease, cerebral ischemia, pneumonia induced by influenza A H1N1, stroke and Alzheimer's disease .
|
-
-
- HY-N6043
-
|
|
Structural Classification
Canarium album (Lour.) Rauesch.
Classification of Application Fields
Phenols
Polyphenols
Plants
Burseraceae
Inflammation/Immunology
Disease Research Fields
Source Classification
|
Apoptosis
Reactive Oxygen Species (ROS)
Bacterial
SARS-CoV
Estrogen Receptor/ERR
|
|
Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
|
-
-
- HY-N2160
-
-
-
- HY-N2125
-
|
|
Structural Classification
Gastrodia elata Bl.
Orchidaceae
Phenols
Plants
Source Classification
|
5-HT Receptor
iGluR
Caspase
Interleukin Related
TNF Receptor
SOD
NF-κB
|
|
Parishin C is a brain-penetrant major bioactive component found in Gastrodia elata Blume. Parishin C is a 5-HT1A receptor agonist with an EC50 of 34 nM. Parishin C has antipsychotic and neuroprotective effects. Parishin C protects against Aβ-induced long-term potentiation damage and NMDA receptor current impairment. Parishin C reduces oxidative stress, pro-inflammatory cytokine levels, caspase activity, brain water content, and cerebral infarct volume; increases antioxidant enzyme activity and BDNF levels; improves nerve function and histopathological brain damage. Parishin C attenuates phencyclidine-induced immobility time increases, sociability deficits, and visual recognition memory impairment. Parishin C can be used for the research of ischemic stroke, Alzheimer's disease, and schizophrenia-like psychosis .
|
-
-
- HY-N0909
-
-
-
- HY-N8249
-
-
-
- HY-W002438
-
-
-
- HY-N14827
-
-
-
- HY-N16499
-
-
-
- HY-N8693
-
|
|
Structural Classification
Withania somnifera
Solanaceae
Plants
Steroids
Source Classification
|
COX
Amyloid-β
Sirtuin
Reactive Oxygen Species (ROS)
Apoptosis
SARS-CoV
|
|
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .
|
-
-
- HY-W005255R
-
|
|
Structural Classification
Monophenols
Microorganisms
Ketones, Aldehydes, Acids
Phenols
Endogenous metabolite
Source Classification
|
Reference Standards
Endogenous Metabolite
|
|
Citrinin (Standard) is the analytical standard of Citrinin. This product is intended for research and analytical applications. Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
|
-
-
- HY-N6746R
-
|
NSC 186 (Standard)
|
Structural Classification
Microorganisms
Ketones, Aldehydes, Acids
Source Classification
|
Reference Standards
Bacterial
Fungal
Endogenous Metabolite
Apoptosis
|
|
Citrinin (Standard) is the analytical standard of Citrinin. This product is intended for research and analytical applications. Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0822S1
-
|
|
|
Fipronil- 13C6 is the 13C-labeled Fipronil. Fipronil is an insecticide that acts as a selective antagonist of insect GABA receptors (IC50s = 30 nM and 1,600 nM for cockroach and rat receptors, respectively). Fipronil also inhibits desensitizing and non-desensitizing glutamate-induced chloride currents in cockroach neurons (IC50s = 800 nM and 10 nM, respectively). Fipronil induces activity of the cytochrome P450 (CYP) isoforms CYP1A1/2, CYP2B1/2, and CYP3A1/2 in isolated rat liver microsomes.
|
-
-
- HY-B0358AS
-
|
|
|
Flunarizine-d8 dihydrochloride is deuterated labeled Flunarizine dihydrochloride (HY-B0358A). Flunarizine dihydrochloride is a potent dual Na +/Ca 2+ channel (T-type) blocker. Flunarizine dihydrochloride is a D2 dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .
|
-
-
- HY-B0168AS
-
|
|
|
Milnacipran-d5 hydrochloride is deuterium labeled Milnacipran hydrochloride (HY-B0168A). Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
-
- HY-N6746S1
-
|
|
|
Citrinin- 13C13 (NSC 186- 13C13) is the 13C labeled Citrinin (HY-N6746). Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
|
-
-
- HY-100658S
-
|
|
|
Didesmethyl cariprazine-d8 is the deuterium labeled Didesmethyl cariprazine (HY-100658). Didesmethyl cariprazine is an orally active, BBB-permeable metabolite of Cariprazine (HY-14763). Didesmethyl cariprazine is a partial agonist at the D2 and D3 receptors, full agonist at the 5-HT1A receptor, and antagonist at the human 5-HT2B receptor (Ki: 1.41 nM (human D2L), 0.056 nM (human D3), 1.7 nM (human 5-HT1A), 0.52 nM (human 5-HT2B)). Didesmethyl cariprazine dose-dependently inhibits the spontaneous activity of rat midbrain dopaminergic neurons.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![[D-Arg25]-Neuropeptide Y (human)](http://file.medchemexpress.com/product_pic/hy-p0198b.gif)
